Universidade do Minho
Escola de Engenharia

Cláudia Sofia Afonso de Lima

Activity of carvacrol against Coagulase-negative Staphylococci biofilm related infections

Outubro de 2015

![Universidade do Minho logo]

Universidade do Minho

Declaração RepositóriUM: Dissertação de Mestrado

Nome: Cláudia Sofia Afonso de Lima

N.º do Cartão de Cidadão/BI: 13765867   Telefone/Telemóvel: 918872207

Correio eletrónico: claudiaafonsolima@gmail.com

Curso: Mestrado em Bioengenharia   Ano de conclusão da dissertação: 2015

Área de Especialização:

Escola de Engenharia, Departamento/Centro: Departamento de Engenharia Biológica

TÍTULO DA DISSERTAÇÃO/TRABALHO DE PROJETO

Título em PT: Atividade do carvacrol em infeções por biofilme de Stafilococus coagulase-negativos

Título em EN: Activity of carvacrol against Coagulase-negative staphylococci biofilm related infections

Orientador: Nuno Cerca

Coorientador: Ângela França

Número de Unidades ECTS da Dissertação: 50   Classificação em valores (0 a 20): 18

Classificação ECTS com base no percentil (A a F):

Declaro sob compromisso de honra que a dissertação agora entregue corresponde à que foi aprovada pelo júri constituído pela Universidade do Minho, UM.

Declaro que concedo à Universidade do Minho e aos seus agentes uma licença não-exclusiva para arquivar e tornar acessível, nomeadamente através do seu repositório institucional, nas condições abaixo indicadas, a minha dissertação, em suporte digital.

Concordo que a minha dissertação seja colocada no repositório da Universidade do Minho com o seguinte estatuto (assinale um):

1. ☐ Disponibilização imediata do trabalho para acesso universal;

2. ☐ Disponibilização do trabalho para acesso exclusivo na UM, durante o período de

   ☐ 1 ano, ☒ 2 anos ou ☐ 3 anos, sendo que após o tempo assinalado autorizo o acesso universal.

3. ☐ Disponibilização do trabalho de acordo com o **Despacho RT-98/2010 c)** (embargo # anos)

Braga, 15 de Outubro de 2015

Assinatura: *Cláudia Sofia Afonso de Lima*

Universidade do Minho
Escola de Engenharia

Cláudia Sofia Afonso de Lima

Activity of carvacrol against Coagulase-negative Staphylococci biofilm related infections

Tese de Mestrado em Bioengenharia

Trabalho efetuado sob a orientação do
Doutor Nuno Miguel Dias Cerca
e co-orientado por
Doutora Ângela Maria Oliveira de Sousa França

Universidade do Minho

Outubro de 2015

This thesis is dedicated to my parents for their love, patience, endless support and encouragement.

"O êxito começa no momento exato em que o homem decide o que quer e começa a trabalhar para o conseguir."

Roberto Shinyashiki

| AGRADECIMENTOS

O sucesso de qualquer projeto depende do esforço e trabalho realizado, mas também do apoio, incentivo e diretrizes de muitas outras pessoas. A realização desta tese de Mestrado foi apenas possível devido ao contributo, direto e indireto, de uma série de pessoas a quem gostaria de expressar a minha gratidão.

Em primeiro lugar, expresso o meu profundo agradecimento ao meu orientador, Doutor Nuno Cerca, pela excecional orientação, conhecimentos transmitidos, exigência e apoio constante que sem dúvida, muito estimularam a minha vontade de querer saber mais e fazer melhor. Agradeço também a oportunidade que me deu de integrar no seu grupo de investigação e reconheço, com gratidão, não só a confiança que em mim depositou, desde o início, mas também, o sentido de responsabilidade que me incutiu em todas as fases do projecto.

Um agradecimento especial a todos os meus colegas do Grupo NC, pela forma como me acolheram e me integraram na equipa, pela ajuda e cooperação, pela discussão e troca de conhecimentos, mas também pelos memoravéis momentos de convívio. Agradeço particularmente à Ângela França, quer pelos conhecimentos transmitidos, quer pelo auxílio prestado, disponibilidade e acompanhamento que fez de todo meu trabalho.

Agradeço a todos os meus colegas de laboratório pela ajuda, companheirismo, boa disposição, e ótimo ambiente de trabalho.

A todos os meus colegas de Mestrado pelos momentos passados, pela entreajuda, boa disposição e ambiente agradável gerado ao longo destes dois anos.

A todos os meus amigos, particularmente ao Nuno Quintão e Jerina Nogueira que apesar da distância, sempre me incentivaram e acreditaram no meu trabalho. Obrigada pela vossa amizade e apoio em momentos mais difíceis.

Ao André Afonso, um agradecimento especial pelo apoio e carinho diários, pelas palavras doces e pela transmissão de confiança e de força, em todos os momentos. Por tudo, o meu enorme obrigado.

Um agradecimento sincero em especial aos meus Pais e Irmão, por acreditarem sempre em mim e naquilo que faço e por todos os ensinamentos de vida. Espero que esta etapa, que agora termino, possa, de alguma forma, retribuir e compensar todo o carinho, apoio e dedicação que, constantemente, me oferecem. A eles, dedico todo este trabalho.

| ABSTRACT

Coagulase-negative staphylococci (CoNS) are frequently found in healthy human skin and mucosae, and hence, have long been considered non-pathogenic bacteria. However, in recent years, they have been recognized as important etiological agents of healthcare-associated infections, being particularly associated with patients with indwelling medical devices. Despite their importance as nosocomial pathogens, very little is known regarding their virulence determinants. Nevertheless, it is recognized that the ability of CoNS to form biofilms play the most important role in their pathogenesis. Biofilms are communities of microorganisms attached to a surface and encased in an extracellular polymeric matrix, which among other functions, protect bacteria from antimicrobial agents allowing, consequently, the progression of infection. In addition, the overuse of antibiotics led to a dramatic rise of resistant bacteria, resulting in an increase in patients' morbidity and in the costs associated with the treatment of these infections. Hence, major efforts need to be made toward the development of new prophylactic and therapeutic strategies for the management of CoNS biofilm-associated infections. The objective of this work is, therefore, to study the susceptibility of CoNS biofilms to carvacrol, a monoterpenic phenol, which presents a wide antimicrobial activity spectrum and is considered as one of the latest novelties in biofilm disruption studies. Carvacrol displayed a significant effect in the viability of planktonic and biofilm cells after a short period of time. Small concentrations (2 µM) were sufficient to exhibit antibacterial effect on these cells. Interestingly, the effect of carvacrol at 2 µM was greater to the effect of vancomycin at peak serum concentration in planktonic cells.

Overall, the results indicate a potential antibacterial effect of carvacrol against CoNS, and therefore the possible action of this molecule on the prevention and treatment of *S. epidermidis* and other CoNS related infections.

Key words: Healthcare-associated infections, Coagulase negative staphylococci, Biofilms, Antibiotic resistance, Carvacrol.

| RESUMO

Os stafilococus coagulase-negativos (CoNS) são frequentemente encontrados na pele e mucosas de pessoas saudáveis e portanto, são normalmente considerados bactérias não patogénicas. No entanto, nos últimos anos foram reconhecidos como agentes etiológicos importantes de infecções nosocomiais, estando particularmente associados a pacientes com dispositivos médicos invasivos. Apesar da sua importancia como patógenos nosocomiais, muito pouco se sabe acerca da sua virulência. Contudo, reconhece-se que a capacidade dos CoNS de formar biofilmes, desempenha o papel mais importante na sua patogénese. Biofilmes são comunidades de microrganismos aderidos a uma superfície e cobertos por uma matriz extracelular polimérica, que, entre outras funções, protege as bactérias de agentes antimicrobianos permitindo, consequentemente, a progressão da infecção. Além disso, a utilização excessiva de antibióticos conduziu a um aumento dramático de bactérias resistentes, resultando num aumento da morbidade e dos custos associados com o tratamento destas infecções. Assim, esforços devem ser feitos para o desenvolvimento de novas estratégias profiláticas e terapêuticas para o controlo de infecções causadas por biofilmes de CoNS. O objetivo deste trabalho foi, portanto, estudar a suscetibilidade dos biofilmes dos CoNS ao carvacrol, um fenol monoterpénico, que apresenta um largo espectro de atividade antimicrobiana e é considerado como uma das mais recentes novidades em estudos de rutura de biofilmes. O carvacrol exibiu um efeito significativo na viabilidade das células planctónicas e de biofilme após um curto período de exposição. Pequenas concentrações (2 µM) foram suficientes para exibir efeito antibacteriano sobre as células. Curiosamente, o efeito de carvacrol a 2 µM em células planctónicas foi superior ao efeito da vancomicina na concentração máxima no soro humano. No geral, os resultados indicam um potencial efeito antibacteriano do carvacrol contra os CoNS, e, portanto, o possível uso desta molécula na prevenção e tratamento de infecções relacionadas com *S. epidermidis* e outros CoNS.

Palavras chave: Infecções associadas aos cuidados de saúde, Stafilococus coagulase-negativos, Biofilmes, Resistência a antibioticos, Carvacrol.

Page Index

| LIST OF IMAGES

| LIST OF TABLES

| ABBREVIATIONS AND ACRONYMS

ATP　　　　Adenosine triphosphate

CDC　　　　Centre for Disease Control and Prevention

CFU　　　　Colony forming units

CSLM　　　Confocal scanning laser microcopy

CoNS　　　Coagulase-negative staphylococci

DNA　　　　Deoxyribonucleic acid

EOs　　　　Essential oils

EPS　　　　Extracellular polymeric substances

EUCAST　　European Commission for Antimicrobial Susceptibility Testing

HAI　　　　Healthcare-associated infection

IUPAC　　　International Union of Pure and Applied Chemistry

MIC　　　　Minimum inhibitory concentration

NaCl　　　　Sodium chloride

LD　　　　　Lethal dose

OD　　　　　Optical density

PBS　　　　Phosphate buffered saline

PNAG　　　Poly-N-acetylglucosamine

TSA　　　　Tryptic soy agar

TSB　　　　Tryptic soy broth

VAN　　　　Vancomycin

Chapter 1| General Introduction

1.1| Healthcare–associated Infections

Healthcare–associated infections (HAI) are defined as a condition that results from an adverse reaction to the presence of an infectious agent(s), or its toxin(s), that occurs during a hospital or clinic stay, for which there is no evidence of the infection, or incubation, at admission (Horan et al., 2008). In general, these infections become manifest 48 hours after initial patient care (Wenzel, 2007). The last HAI prevalence survey provided by the Centre for Disease Control and Prevention (CDC) estimated, that in 2011, 1 in 25 patients hospitalized in U.S.A. acute care hospitals contracts at least one HAI and about 75,000 die during their hospitalization.

Table 1.1. Estimated number of HAI occurring in acute care hospitals in the U.S.A. during 2011. Adapted from CDC HAI Prevalence Survey (Magill et al., 2014).

Major site of infection	Estimated numbers of infections
Pneumonia	157,500
Gastrointestinal illness	123,100
Urinary tract infections	93,300
Primary bloodstream infections	71,900
Surgical site infections	157,500
Other types of HAI	118,500

Despite the progress observed in healthcare in the last years, infections continue to rise in hospitalized patients affecting, as well, hospital staff (Stone et al., 2008). Several factors such as decreased immunity and the increasing use of invasive techniques or implantation of medical devices (Von Eiff et al., 2005) can promote infection among hospitalized patients. The incidence of medical devices-associated infections is higher in the case of skin penetrating devices as these may bring together members of the normal skin flora. Coagulase-negative staphylococci (CoNS), are considered one of the main causes of medical devices-related nosocomial infections due to their ubiquity in the normal skin flora and mucosae (Rogers et al., 2009). The contamination of medical devices can also occur from the hands of the

surgical or clinical staff, contaminated disinfectants, other patients or distant local infections (McCann et al., 2008; Pittet et al., 1999; von Eiff et al., 2002).

1.2| Coagulase-Negative Staphylococci and its pathogenesis

Staphylococci are members of the family *Micrococcaceae* and belong to genus *Staphylococcus*. They are non-motile, non-spore-forming, Gram-positive, facultative anaerobic and clustering cocci that produce catalase (Pfaller and Herwaldt, 1988). On a solid culture medium, staphylococcal species exhibit different colony morphologies. While *S. aureus* produces large yellow colonies, CoNS species usually form relatively small white-greyish colonies. Until 1975, CoNS were grouped together as *S. albus* or *S. epidermidis*, and were distinguished from *S. aureus* by their inability to clot blood (Huebner and Goldmann, 1999; Mansour et al., 2009). Nowadays, there are 49 recognized CoNS species (Euzéby, 1997).

a)   **b)**

Figure 1.1. *Staphylococcus* **under the microscope (a)** Gram-stain of a staphylococcus culture **(b)** Scanning electron microscopy image of staphylococci showing their clustered organization.
Adapted, respectively, from http://www.microbiologyinpictures.com/staphylococcus%20aureus.html and http://textbookofbacteriology.net/staph.html [Accessed at 25 March 2015].

As referred before, CoNS are an important integrant and integrant part of the normal flora of human skin and mucosae. Certain CoNS species prefer particular niches, while others occur almost everywhere on our body (Grice and Segre, 2011). *S. epidermidis,* the most frequently isolated CoNS*,* colonizes several areas such as the axilla, groin, mucous membranes and exposed skin surfaces (Huebner and Goldmann,

1999). In addition, the colonization by *S. epidermidis* plays an important role in the maintenance of a healthy flora, by competing with potentially harmful microorganisms such *S. aureus* (Fey and Olson, 2010).

The insertion or implantation of foreign bodies, such as prosthetic heart valves, cardiac pacemakers, total artificial hearts and joint replacements, intravascular catheters, cerebrospinal fluid and renal dialysis shunts or continuous ambulatory peritoneal dialysis catheters, have become indispensable in modern medicine (Von Eiff et al., 2005). Nowadays, for instance, a considerable number of patients have one or even more than one vascular catheters in place during their hospitalization (Service and Services, 2003). However, unfortunately, the use of foreign material has been associated with the onset of severe bacterial and fungal infections (Bonadio, 2006; Halebeedu et al., 2014).

While a variety of Gram-positive and negative bacteria, as well as fungi, have been recognized as important causative agents of foreign body-related infections, staphylococci, particularly *S. epidermidis* and other CoNS, account for the majority of infections, including both temporarily inserted and permanently implanted material (Donlan, 2001; Hugonnet et al., 2004; Kleeman et al., 1993).

Table 1.2. List of implanted medical devices more often colonized by CoNS. Adapted from (Darouiche, 2001; Lynch and Robertson, 2008).

Device	Estimated no. inserted in the U.S.A per year	Rate of infection (%)	Attributable mortality
Bladder catheters	>30,000,000	10–30	Low
Central venous catheters	5,000,000	3–8	Moderate
Fracture fixation devices	2,000,000	5–10	Low
Dental implants	1,000,000	5–10	Low
Joint prostheses	600,000	1–3	Low
Vascular grafts	450,000	1–5	Moderate
Cardiac pacemakers	300,000	1–7	Moderate
Mammary implants	130,000	1–2	Low
Mechanical heart valves	85,000	1–3	High
Heart assist devices	700	25–50	High

However, in recent years, *S. epidermidis* and other CoNS have become important opportunistic pathogens being especially problematic in patients with indwelling medical devices (Otto, 2011) (Table 2). *S. epidermidis*, for instance, is one of the most frequent causative agents of indwelling medical devices-associated infections, being particularly associated with peripheral and central intravenous catheters (Otto, 2009; Rogers et al., 2009). These infections usually begin with the introduction of this bacterium from the skin of the patient, or healthcare personnel, during catheter insertion (Rogers et al., 2009) being particularly increased in the last years, due to the increased use of such devices in the clinical setting (Nnis, 2004; Toole et al., 2000). Bloodstream infections occur in at least 4–5 out of every 1,000 catheters insertions performed on patients in intensive care in the U.S.A, and at least 22% of these infections are caused by *S. epidermidis* (Hall-Stoodley and Stoodley, 2009; Nnis, 2004; Otto, 2009).

Table 1.3. Rank of nosocomial bloodstream pathogens and the associated crude mortality among 49 hospitals throughout the U.S.A. Adapted from (Edmond et al., 1999).

Rank	Pathogen	Number of isolates	%	Crude mortality (%)
1	Coagulase-negative staphylococci	3,908	31.9	21
2	*Staphylococcus aureus*	1,928	15.7	25
3	Enterococci	1,354	11.1	32
4	*Candida* spp	934	7.6	40
5	*Escherichia coli*	700	5.7	24
6	*Klebsiella* spp	622	5.4	27
7	*Pseudomonas* spp	557	4.5	28

S. epidermidis is also frequently associated with prosthetic joint, vascular graft, surgical site, central nervous system shunt and cardiac device infections (Otto, 2009). Nevertheless, other CoNS are often implicated in HAI onset. *S. haemolyticus*, for instance, it is second only to *S. epidermidis* in its frequency of isolation and has been associated with the development of important infections such as peritonitis, otitis media, urinary tract infections and septicemia (Akinkunmi and Lamikanra, 2010).

Other CoNS species with clinical significance include *S. hominis*, *S. warneri*, *S. capitis* and *S. equorum* (Delmas et al., 2008), being the 3 first found less frequently (John and Harvin, 2007). To what concerns CoNS virulence determinants, the most important characteristic is their capability to form biofilms on the surface of implanted foreign bodies (Goldmann and Pier, 1993; Longauerova, 2006).

1.3| Impact of CoNS Biofilms

Biofilms are defined as a sophisticated community of matrix-encased, surface-attached bacteria that exhibit a particular phenotype. They are highly hydrated structures composed of 73 to 98% of extracellular material (Freitas, 2003), and contain channels that allow the inward diffusion of nutrients and oxygen to maintain the viability and capacity to proliferate. Biofilms may also contain non-microbial host derived components (Donlan, 2002). Among others functions, it was shown that biofilm formation in *S. epidermidis* and CoNS protects bacteria from antibiotics (Cerca et al., 2005a) and also from the host immune system (Cerca et al., 2005b; Costerton et al., 2005; Longauerova, 2006) resulting in infections that can linger for months, years, or even a lifetime (Costerton et al., 1999). Evidently this has serious clinical implications as it results in the emergence of chronic and persistent infections (Costerton et al., 1999). Indeed, it was shown that biofilms are implicated in more than 80% of the diagnosed chronic infections caused by bacteria including *S. epidermidis* and others CoNS (Otto, 2009; Sauer et al., 2007). Although *S. epidermidis* infections are rarely fatal, they significantly compromise patients' quality of life often implicating the removal of the infected device in order to treat the infection. In addition to the clear human consequences, these infections increase healthcare system outgoings, due to the costs associated with the diagnosis and treatment of such infections (Stewart and William Costerton, 2001).

Henceforth, in order to better understand the origin of biofilm-related infections, the study of the mechanisms underlying biofilm formation has been extensively explored in the last years.

1.3.1| Mechanism of Biofilm formation

Biofilm formation is classically defined as a four-step process which includes: (1) adherence, (2) accumulation of cells in multiple layers, (3) maturation and (4) detachment (Fey and Olson, 2010; Stoodley et al., 2002). The initial step in biofilm formation, the attachment, can occur through direct binding to the native surface of a medical device or, via interaction with host extracellular matrix proteins present in the conditioning film that rapidly forms on the surface of medical devices following implantation (Vacheethasanee et al., 1998). The bacterial proteins that mediate binding to medical devices surfaces have been identified. In *S. epidermidis*, these include the bifunctional adhesins/autolysins AtlE and Aae (Heilmann et al., 2003, 1997; Williams et al., 2002) and multiple adherence factors, known as microbial surface components recognizing adhesive matrix molecules, which specifically interact with human serum proteins coating the implanted medical device (Clarke and Foster, 2006).

After adherence, bacterial cells rapidly grow leading to the accumulation of cellular aggregates, which results in small adherent micro colonies coalescing to form large coherent bacterial biofilm (Choong and Whitfield, 2000). These aggregates are then embedded within a matrix of extracellular polymeric substances, which is composed, among other components, by extracellular DNA, proteins, lipids and polysaccharides (Hall-Stoodley and Stoodley, 2009).

The maturation stage is facilitated by the increased transcription of genes that codify specific adhesion molecules, such as poly-N-acetylglucosamine (PNAG) (Mack et al., 1996), which cement the bacterial cells to the surface and to each other, giving rise to the characteristic biofilm structure (Choong and Whitfield, 2000). Finally, bacteria slowly proliferate and detach from the biofilm into the surrounding environment, enabling bacteria to colonize new surfaces and renew biofilm formation cycle elsewhere.

Figure 1.2. Model of *Staphylococcus* biofilm development. At stage (1), the bacterial cells attach to the surface. At the next stage (2), bacterial cells accumulate in multiple layers resulting in the formation of micro colonies. Then, at stage (3), the maturation phase is reached, as indicated by the complex biofilm architecture obtained. At the detachment stage (4), single or clusters of cells leave the biofilm in to the involving environment. Image adapted from (Vuong and Otto, 2002).

1.4| Biofilms and antibiotics resistance

Since the discovery of penicillin in 1928s, antibiotics have been considered one of the wonder discoveries of the 20th century. Antibiotics have been critical in fighting infectious diseases caused by bacteria and other microbes, consequently increasing the average of life expectancy. However, concomitantly, antibiotic resistance has risen (Davies and Davies, 2010). Over the past several decades, the frequency of antimicrobial resistance and its association with the onset of serious infectious diseases have increased at alarming rates, resulting in an upsurge of morbidity, mortality, although less frequent in CoNS, and the costs associated with diagnosis and treatment of these infections (Davies and Davies, 2010). The way antibiotics are available to the population played an important role in the current massive use of antibiotics and, subsequently, in the emergence of an antibiotic resistance Era (Turnidge and Christiansen, 2005).

Antimicrobial resistance and/or tolerance in CoNS became an issue in the 1970s when CoNS species were isolated, for the first time, from prosthetic valve endocarditis and cerebrospinal fluid shunt infections (Odonkor and Addo, 2011). Since then, the treatment of CoNS infections has become increasingly difficult due to the high

prevalence of antibiotic-resistant strains and the increased antibiotic tolerance inherent to biofilm formation.

1.4.1| Mechanisms of antibiotic resistance

By interacting with specific bacterial targets, antibiotics are able to inhibit, among others, bacterial cell-wall synthesis, protein synthesis or nucleic acid replication and transcription (Kohanski et al., 2010). Evidently, to accomplish its function, antibiotics must have access to and bind to its bacterial target. Over the years, bacteria have developed several mechanisms to circumvent antibiotics action. Most of the mechanisms employed by bacteria do not destroy or inactivate antibiotics but rather changes the antibiotic target or export it out of the cell (e.g. efflux pumps). In the last case, antibiotics are released into the surrounding environment in their active form, continuing to exert their selective pressure (Levy and Marshall, 2004).

In general, antibiotic resistance mechanisms fall into three broad categories: 1) direct inactivation of the active molecule, 2) alteration of the organism sensitivity to the antibiotic by modification of the target site, and 3) reduction of the concentration of drug that reaches the target (Hogan and Kolter, 2002). The mechanisms within the first category include the production of enzymes that degrade or modify the drug itself (Dzidic et al., 2008). Regarding the second category, the decreased sensitivity to antibiotics due to target modification, comprehend diverse microbial strategies such as the production of structure-altering or inactivating enzymes (e.g. β-lactamases or amino glycoside-modifying enzymes) (Paterson, 2001), alteration of penicillin-binding proteins or other cell-wall target sites (Brakstad and Maeland, 1997), altered DNA gyrase targets (Bearden and Danziger, 2001), mutations and ribosomal modification (Dzidic and Bedeković, 2003). However, most of the recent excitement in the field of antibiotic resistance is focused in the third category of antibiotic resistance mechanisms, the reduction of the antibiotic concentration at the target site.

In biofilms, despite the above referred mechanisms, there are other particular factors contributing to the inconsistent success of antimicrobial therapy (Alekshun and Levy, 2007). Although is still unclear which are all the biofilm-specific mechanisms that result in antibiotics tolerance, the barrier diffusion created by the biofilm matrix

10

(Donlan and Costerton, 2002), slow growth rate of the cells within biofilms (Costerton et al., 1999; Gilbert et al., 2002; Percival et al., 2011), the induction of antibiotic tolerant phenotypes (Percival et al., 2011), as well as the acquisition of genetic material are some of the factors known so far (Kokare et al., 2009).


Figure 1.3. Three hypotheses proposed for antibiotic tolerance in biofilms. 1) Antibiotic (yellow) may fail to penetrate beyond the surface layers of the biofilm; 2) some of the biofilm cells may differentiate into a protected phenotypic state (green); 3) in zones of nutrient depletion or waste accumulation (pink), antibiotic action may be antagonized and 4) persisters (purple) are cells that neither grow nor die in the presence of bactericidal agents, exhibiting multidrug tolerance. Image adapted from (Stewart and William Costerton, 2001).

1.4.1.1| Antimicrobial penetration failure

When microorganisms grow in planktonic culture, diffusion is not an issue. Planktonic cultures are generally agitated, and the fluid flow rapidly transports solutes to all cells. Diffusion limitation arises in biofilms. Fluid flow is reduced and the diffusion distance is increased (Stewart, 2003) in biofilms due to the high cell density and the presence of extracellular polymeric substances that arrest the flow of water. Since diffusion is the principal transport process in cells aggregates (De Beer et al., 1997), antimicrobial agents have difficulty to penetrate the biofilm structure. Some studies showed, however, that the extracellular polymeric matrix does not form an impenetrable barrier to the diffusion of antimicrobial agents (Cho, 2007; Donlan and Costerton, 2002; Percival and Bowler, 2004), and hence, other mechanisms must be occurring in order to protect biofilm cells from antibiotics action (Dunne et al., 1993; Percival and Bowler, 2004).

1.4.1.2| Slow growth rate

The transition from exponential to slower or no growth is generally accompanied by an increase in tolerance to antibiotics (Butler et al., 2010; Stewart, 2003). Antibiotics can kill bacteria by interfering with their cell wall, causing the cell to break open or lyse (Kohanski et al., 2010; Neu and Gootz, 1996). Hence, the antimicrobials that target bacterial cell wall are more effective in rapidly than slow growing cells. The efficacy of penicillin and ampicillin, for instance, is directly proportional to the rate of growth, being unable to kill non-growing cells (Lewis et al., 2001). Some of the more advanced β-lactams, cephalosporins, aminoglycosides and fluoroquinolones can kill non-growing cells, but they are clearly more effective in rapidly dividing cells (Costerton et al., 1999). However, other studies suggested that some determinants other than growth rate may be responsible for tolerance, and slow growth just enhances the effect (Duguid et al., 1992).

1.4.1.3| Resistance genes

Antibiotic resistance may be 1) intrinsic or 2) acquired (Neu, 1992). Intrinsic resistance is normally associated with the occurrence of genetic mutations in the bacterial chromosomal DNA, whereas acquired resistance is often related with horizontal gene transfer, which involves the acquisition of new genetic material. Mutations are generally uncommon events but may result in the development of antibiotic resistance in organisms that were initially susceptible (Mulvey and Simor, 2009). However, the development of resistance through the acquisition of new genetic material is of greater concern in the biofilm mode of growth since biofilms are an ideal niche for the exchange of extrachromosomal DNA (Donlan, 2002). Hence, this mechanism plays an important role in the dissemination of antibiotic resistance among strains or among different bacterial species or genera constituting a biofilm (Dzidic and Bedeković, 2003). Mechanisms associated with genetic transfer include conjugation, transformation and transduction (Tenover, 2006). Conjugation, the mechanism by which the bacterial plasmid may be transferred to other bacteria, occurs at a greater rate within biofilms than among planktonic cells (Hausner and Wuertz, 1999; Roberts et al., 1999) as the biofilm environment provides minimal

shear and closer cell-to-cell contact (Donlan, 2002; McCarty et al., 2014; Prakash et al., 2003). Since plasmids may encode several resistance genes, conjugation provide an extraordinary mechanism to the spread of antimicrobial resistance genes (Donlan, 2002). Because antibiotic resistance occurs as part of a natural process in which bacteria evolve, it cannot be stopped (Frieden, 2013). There is, therefore, an urgent need to find alternative strategies in order to control resistant bacteria.

1.5| New approaches for biofilm infections prevention and therapy

The rapid development of antimicrobial drug-resistant pathogens is amongst the most serious threats to public health nowadays (Lai et al., 2011; Lambert et al., 2011). As a result, during the last few years the scientific community has shown considerable interest in the study of plant elements as antimicrobial agents in order to be used for new prophylactic and therapeutic strategies (Nostro and Papalia, 2012).

1.5.1| Essential oils

Essential oils (EOs) are aromatic oily liquids, most commonly obtained by steam distillation, found in plant constituents such as flowers, buds, seeds, leaves, twigs, bark, herbs, wood, fruits and roots (van de Braak et al., 1994). In the past, several EOs were identified and commercialized by their flavors and fragrances (van de Braak et al., 1994), as dental canal sealers (Manabe et al., 1987), antiseptics (Cox et al., 2000) and also used as food supplements (Ilsley et al., 2002). In addition, EOs are known, for a long time, by their antimicrobial and antioxidant properties (Guenther, 1948) and several studies have been conducted in order to evaluate their action in several bacteria, viruses and fungi (Kalemba and Kunicka, 2003; Reichling et al., 2009; Solórzano-Santos and Miranda-Novales, 2012).

Table 1.4. Major chemical components of EOs that exhibit antibacterial properties.

Common name of EO	Plant source	Major components	Approximate composition (%)[a]	References
Cilantro	*Coriandrum sativum*	Linalool E-2-decanal	26% 20%	(Delaquis et al., 2002)
Coriander	*Coriandrum sativum*	Linalool	70%	(Delaquis et al., 2002)
Cinnamon	*Cinnamomum zeylandicum*	Trans-cinnamaldehyde	65%	(Lens-Lisbonne et al., 1987)
Oregano	*Origanum vulgare*	Carvacrol Thymol λ-Terpinene p-Cymene	Trace-80% Trace-64% 2 –52% Trace-52%	(Daferera et al., 2000; Demetzos et al., 2001; Kokkini et al., 1997; Lawrence, 1984; Marino et al., 2001; Russo et al., 1998; Sivropoulou et al., 1996)
Thyme	*Thymus vulgaris*	Thymol Carvacrol λ-Terpinene p-Cymene	10–64% 2–11% 2–31% 10–56%	(Cosentino et al., 1999; Daferera et al., 2000; Juliano et al., 2000a; Lens-Lisbonne et al., 1987; Marino et al., 1999; Mcgimpsey et al., 1994)
Sage	*Salvia officinalis L.*	Camphor α-Pinene β-pinene 1,8-cineole α-tujone	6–15% 4–5% 2–10% 6–14% 20–42%	(Marino et al., 2001)

[a] Percentages of total volatiles rounded up to the nearest whole number. EO-essential oil.

The composition of EOs from different plants is distinct and, in particular species, can also differ among harvesting seasons and geographical sources (Cosentino et al., 1999; Faleiro et al., 2003; Juliano et al., 2000b; Marotti et al., 1994; Mcgimpsey et al., 1994). Generally, EOs produced from herbs harvested during, or immediately after flowering processes, present the strongest antimicrobial activity (Marino et al., 1999). However, the composition, and consequently, the action of the EOs obtained from different parts of the same plant can vary widely (Delaquis et al., 2002). Although the antimicrobial properties of EOs and their components have been reviewed in the past (Nychas, 1995; Shelef, 1984), their exact mechanism of action is still unknown

(Lambert et al., 2001). Considering the large number of different groups of chemical compounds that compose EOs, it is most likely that their antibacterial activity is not determined by one specific mechanism or target, but by several mechanisms or targets in the cell (Carson et al., 2002; Skandamis et al., 2001).

The mechanisms of action of the EOs known so far include: 1) the degradation of the cell wall (Gill and Holley, 2006; Helander et al., 1998), 2) cytoplasmic membrane damage (Oosterhaven et al., 1995; Ultee et al., 2002, 2000), 3) cytoplasm coagulation (Gustafson et al., 1998; Ultee et al., 2002, 2000), 4) membrane proteins damage (Juven et al., 1994; Ultee et al., 1999), 5) increased permeability due to increased hydrolysis and reduced membrane potential resulting in leakage of the cells contents (Burt, 2004; Cox et al., 2000; Gustafson et al., 1998; Helander et al., 1998; Juven et al., 1994; Lambert et al., 2001; Oosterhaven et al., 1995; Ultee et al., 2002), 6) reduced proton motive force (Ultee and Smid, 2001; Ultee et al., 1999), and 7) reduced intracellular ATP pool via decreased ATP synthesis (Burt, 2004). It is important to emphasize that not all of the enumerated mechanisms are separate targets, some are affected indirectly, as a consequence of another mechanism being targeted (Burt, 2004).


Figure 1.4. Mechanisms of action and target sites of EOs in microbial cells: 1) degradation of the cell wall; 2) cytoplasmic membrane damage; 3) coagulation of cytoplasm; 4) membrane proteins damage; 5) increased permeability resulting in leakage of cell contents; 6) depletion of the proton motive force; 7) reduction of ATP pool.

It has been shown that EOs with higher percentage of phenolic compounds, such as carvacrol, eugenol and thymol, retain the strongest antibacterial properties (Cosentino et al., 1999; Dorman and Deans, 2000; Juliano et al., 2000b; Lambert et al., 2001). Carvacrol has proven to have better antimicrobial properties when compared with parent compounds (Mastelić et al., 2008). Because of its promising antimicrobial effect, carvacrol became a compound of interest in the search for new approaches for biofilms infections treatment (Borges et al., 2013; Iannitelli et al., 2011).

1.5.2| Carvacrol

Since biofilm resistance depends, at some extent, on their multicellular structure, one possible strategy for the management of biofilm-associated infections is to develop therapies that disrupt its multicellular structure (Percival et al., 2011). If its multicellularity is defeated the efficacy of antibiotics might be restored and the host defenses might also be able to resolve the infection (Stewart and William Costerton, 2001).

Potential therapies under evaluation comprise, among others, the use of enzymes that degrade the polymers of the biofilm matrix (Nemoto et al., 2000; Parsek and Greenberg, 2000; Yasuda et al., 1993) and the use of molecules capable of interfering with cell-cell interaction required for normal biofilm formation.

Carvacrol, (2-methyl-5-(1-methylethyl)-phenol), is one of the most common components of the EOs of the family *Labiatae* (Başer and Demirci, 2007; Kirimer et al., 1995; Nostro et al., 2012; Solórzano-Santos and Miranda-Novales, 2012). As a monoterpenic phenol, carvacrol is mainly found in several aromatic plants such as thyme, oregano, wild bergamot and pepperwort (Singh and Chittenden, 2010). Due to carvacrol wide range of biological properties, which includes: 1) antibacterial (Aligiannis et al., 2001; Pérez-Conesa et al., 2011; Rivas et al., 2010; Svoboda and Hampson, 1999), 2) antifungal (Ahmad et al., 2011; Dalleau et al., 2008), 3) antitumor (Arunasree, 2010; Karkabounas et al., 2006), 4) antioxidant (Aristatile et al., 2011; Jayakumar et al., 2012; Prieto et al., 2007), 5) antiinflammatory (Hajhashemi et al.,

2002; Hotta et al., 2010; Landa et al., 2009), 6) anti-obesity (Cho et al., 2012), 7) antidepressant/anxiolytic (Melo et al., 2010), 8) insecticidal, (Karpouhtsis et al., 1998; Park et al., 2005), 9) antispasmolytic (Boskabady et al., 2011) and 10) vasorelaxant (Earley et al., 2010; Peixoto-Neves et al., 2010) activities, the interest in its use as therapeutic agent has been increasing.

Table 1.5. Carvacrol structure and its physico-chemical properties. Adapted from (Nostro and Papalia, 2012)

|	
	IUPAC name: 2-methyl-5-(1-methylethyl) phenol
	Molecular formula: $C_{10}H_{14}O$
	Molecular weight: 150.22 g/mol
	Physical state: Liquid (oily)
	Solubility (ppm): 830±10
	LD$_{50}$ (p.o. rats) 810 mg/Kg

The antibacterial activity of carvacrol has been attributed to its hydrophobic nature, the presence of a free hydroxyl group and a delocalized electron system (de Sousa et al., 2012; Nostro et al., 2009). Its free hydroxyl group interacts with the lipid bilayer of the cytoplasmatic membrane causing the expansion and destabilization of the membrane structure increasing membrane fluidity and permeability to protons and ions, resulting in loss of integrity (Ben Arfa et al., 2006; Cristani et al., 2007; Helander et al., 1998; Lambert et al., 2001; Ultee et al., 1999). Moreover, studies performed in *Bacillus cereus* demonstrated that carvacrol damages bacterial cell membrane by pushing apart the fatty acid chains of the phospholipids layer, creating channels that allow ions leakage from the cytoplasm (Ultee et al., 2000). In addition, numerous reports have shown that carvacrol has a potent action against bacteria, yeasts and fungi (Altintas et al., 2013; Camele et al., 2014; Kalemba and Kunicka, 2003; Nostro et al., 2009; Reichling et al., 2009; Solórzano-Santos and Miranda-Novales, 2012), even in drug-resistant species (Chami et al., 2005; Dorman and Deans, 2000; Ultee et

al., 1998). It has also been shown that both *S. aureus* and *S. epidermidis*, including methicillin-resistant strains, are susceptible to carvacrol (Nostro et al., 2004). Furthermore, it has been reported that carvacrol is able to inhibit the growth of preformed biofilms and to interfere with biofilm formation of numerous species, including *S. epidermidis* (Knowles and Roller, 2001; Knowles et al., 2005; Nostro et al., 2009, 2007, 2004).

Taking into consideration the increasing incidence and prevalence of CoNS biofilm-related infections and the emergence of multidrug resistance, there is an urgent need to find new and effective therapies for the management of CoNS biofilm-associated infections. Herein, we investigated the susceptibility of different CoNS biofilms to the action of carvacrol.

Chapter 2| Materials and Methods

2.1| Bacteria and growth conditions

For this study the biofilm-forming species *S. epidermidis* strain 20A.1, *S. equorum strain 060A, S. haemolyticus strain 065A.1, S. hominis strain M11, S. capitis strain 52A and S. wameri* strain F16 were used. These strains were previously isolated and characterized by (Oliveira and Cerca, 2013). All strains were prepared by inoculating a single colony into 2 mL of Tryptic Soy Broth (TSB) (Liofilchem, Roseto Degli Abruzzi, Italy) and incubating at 37°C with shaking at 200 rpm for 24 (±2) hours.

Planktonic cultures were attained by diluting (1:200) the 24 hours-old culture in 2 mL of fresh TSB and by incubating at 37°C and 200 rpm for additional 6 or 24 (± 2) hours in order to obtain, respectively, exponential or stationary phase planktonic cells.

Biofilms were formed as described previously (Cerca et al., 2012b) with some modifications. In brief, in a 96-well microtitre plate (Orange Scientific, Braine- l'Alleud, Belgium), 2 μL of the 24 hours-old culture was inoculated into 200 μL of TSB supplemented with 0.25% of glucose to promote biofilm formation. The plates were then incubated for 24 hours at 37°C with shaking at 120 rpm to allow biofilm formation. Thereafter, prior to any experiment, spent medium, was carefully removed and biofilms washed once with 200 μL of 0.9% NaCl.

2.2| Optical density versus colony forming units

In order to be able to adjust the same concentration of bacteria in the planktonic or biofilms cultures, the optical density, at 640 nm, and the number of colony forming units per mL (CFU) were determined. Summarily, after 24 hours of growth, biofilms were suspended in 0.2 mL of 0.9% NaCl solution by scrapping the biomass attached to the bottom of the well. For each strain, a pool of three biofilms was performed. Then, both biofilm and planktonic cells were harvested by centrifugation at 13500 *g* during 10 minutes, suspended in 1 mL of 0.9% NaCl supplemented with 0.05% Tween20 (0.9% NaCl tween) (Applichem, Darmstadt, Germany) and sonicated, on ice, for 3 seconds at 40% amplitude (Cole Parmer Ultrasonic Processor, Illinois, USA). This procedure eliminated bacterial aggregates that would interfere with posterior CFU

counting (Cerca et al., 2011). Subsequently, 10-fold dilutions were performed in 0.9% NaCl tween and plated on Tryptic Soy Agar plates. Plates were then incubated at 37°C overnight to allow CFU counting. For optical density readings at 640 nm, both planktonic and biofilm cultures were diluted 1:10, respectively, in TSB and 0.9% Nacl. The values of optical density and the respective number of CFU per mL were plotted in order to allow the correlation between OD readings and concentration of cells. This experiment was performed three independent times.

2.3| Determination of carvacrol minimum inhibitory concentration (MIC)

The determination of carvacrol minimum inhibitory concentration in planktonic cultures of the different CoNS isolates under study was evaluated by the broth microdilution method, adapted from (Clinical and Laboratory Standards Institute, 2012). Briefly, in a 96-well microtiter plate (Orange Scientific, Braine-l'Alleud, Belgium), carvacrol (Sigma, MO, USA), initially dissolved in dimethyl sulfoxide was serially diluted (1:2) in TSB in order to obtain carvacrol concentrations ranging from 4 µM to 0 µM. Then, each dilution was inoculated with 2 µL of a planktonic cells suspension with approximately 1×10^8 CFU/mL, equivalent to an OD_{640nm} of 0.16. The plate was incubated at 37°C during 24 (±2) hours without shaking. Bacterial growth, in the presence or absence of carvacrol, was evaluated by direct visualization of medium turbidity. Carvacrol MIC was defined as the lowest concentration of carvacrol that prevented bacterial growth. This experiment was repeated three independent times.

2.4| Planktonic cells and biofilms susceptibility to carvacrol and vancomycin assessed by CFU counting

For the analysis of the effect of both carvacrol and vancomycin in the different CoNS isolates under study, planktonic cells, grown as described above, were incubated, for 5, 50, 95 and 185 minutes, with carvacrol (2 µM, 4 µM, 8 µM, 16 µM) or vancomycin (40 µL/mL) which represent vancomycin peak serum concentration (Boselli et al.,

2005). Biofilms cultures were exposed for 5, 50 and 95 minutes, with carvacrol MIC (2 µM) or vancomycin (40 µL/mL). A control was achieved by plating both planktonic and biofilm cells before addition of carvacrol or vancomycin.

After exposure to carvacrol and vancomycin, the number of culturable cells in both planktonic cells and biofilms was assessed by CFU counting. Prior to cells collection, biofilms were washed once and suspended in 0.2 mL of 0.9% NaCl. For each species, a pool of three biofilms was performed. Thereafter, biofilm and planktonic cells were collected by centrifugation, suspended in 1 mL of 0.9% NaCl tween, sonicated and plated as described in "Optical density versus colony forming units calibration curve". This experiment was performed five times for planktonic cells and three times for biofilms.

2.5| Assessment of bacteria death by flow cytometry

The viability of planktonic cells exposed to carvacrol was evaluated by flow cytometry, using Live/Dead staining, as previously optimized (Cerca et al., 2011) with minor modifications. In brief, a control with dead cells was obtained by incubating bacteria, 15 min on ice, with 1 mL of 99% methanol (Fisher, LE, UK). Subsequently, bacteria were collected by centrifugation and suspended in 1 mL of phosphate buffered saline (PBS). Then, 10 µL aliquots were collected, from both controls and treated planktonic cells, and mixed with 90 µL of PBS containing 1:80000 SYBR®Safe DNA gel stain (Invitrogen, CA, USA) and 20 µg/mL of propidium iodide (Sigma, MO, USA). Samples were then analyzed in an EC800™ flow cytometer (Sony Biotech Inc., CA, USA) using the 488 nm laser and at a 10 µL/min flow rate. SYBR green was detected in the FL1 (525/50 nm) and propidium iodide in the FL4 (615/30) filter. Data were acquired and analyzed using EC800™ software version 1.3.6 (Sony Biotech Inc). This experiment was performed once for confirmation of CFU counting results.

2.6| Confocal laser scanning microscopy of biofilms exposed to carvacrol

Biofilms were prepared for confocal scanning laser microcopy (CSLM) as described above, with some modifications. Shortly, in a 24-well polystyrene plate (Thermo Fisher Scientific, New York, USA), 5 µL of a 24 hours growth was inoculated into 1 mL of TSB supplemented with 0.25% glucose and incubated, for 24 hours (±2), at 37 °C and shaking at 120 rpm. Carvacrol treatment was performed using 200 µL of carvacrol at 2 µM concentration for 95 minutes of incubation. Then, biofilms were washed with 0.9% NaCl solution to remove planktonic cells and carvacrol residues. Afterwards, the bottom of each well, was removed using a metal heat cutter with a similar diameter of the wells. Biofilms were then stained with SYTO9 (485/498 nm) (Molecular Probe, city, USA) following the manufacturer's instructions and placed on the top of a glass slide.

Biofilms images were obtained using an Olympus™ FluoView FV1000 (Olympus, Lisboa, Portugal) confocal scanning laser microscope. Biofilms formed by all CoNS strains were observed using a 60 × water-immersion objective (60 ×/ 1.2 W). Images were acquired with 512 × 512 resolution and in at least two different regions of each surface analyzed. For biofilm maximum thickness determination, at least ten different regions per surface were analyzed, by determining the top and bottom layer of the biofilm. This experiment was performed twice.

2.7| Statistical analysis

Statistical significance between control and treated samples was determined by Student's t-test using Microsoft®Excel® 2013 software (Santa Rosa, CA, USA). Differences were considered significant when P values were less than 0.05.

Chapter 3| Results and Discussion

Conventional treatment of *S. epidermidis* and others CoNS infections, including those caused by biofilms on implanted medical devices, involves the use of common antibiotic therapy (McCann et al., 2008). Biofilm infections are very difficult to treat, especially due to the increasing resistance to antibacterial agents (Folkesson et al., 2008; McCann et al., 2008). Treatment with antibiotics commonly fails to eradicate cells embedded within the biofilm, which can then result in the onset of recurrent and relapsing infections (Donlan and Costerton, 2002).Therefore, new strategies to control *S. epidermidis* and other CoNS biofilm infections are required.

3.1| Carvacrol MIC determination

In the first stage of this research project it became essential to understand if strains were susceptible to the antimicrobial agent or not. Therefore, the first step was to assess the MIC of carvacrol. The results obtained for all six CoNS strains used are summarized in Table 1.

Table 3.1. Evaluation of the minimum inhibitory concentration of carvacrol on the six CoNS isolates under study.

Strain	MIC range (µM)
S. equorum 060A	1 - 2
S. haemolyticus 065A.1	1 - 2
S. hominis M11	1 - 2
S. capitis 52A	2
S. warneri F16	2
S. epidermidis 20A.1	2

The results shown in Table 3.1 indicate that all the CoNS strains used in this study were susceptible to low concentrations of carvacrol, which was consistent with the results found in the literature for *S. epidermidis* (Nostro et al., 2007).

3.2| Evaluation of carvacrol activity on planktonic cultures

Biofilm formation, as mentioned previously, is the major virulence factor of *S. epidermidis* (Vuong and Otto, 2002), as well as other CoNS species being frequently associated with biofilm-associated nosocomial infections (Otto, 2008). Therefore it is of particular interest to address the action of carvacrol in *S. epidermidis* biofilms and other CoNS species.

In order to correlate results from carvacrol effect on planktonic and biofilm cultures, we first characterized the biofilms formed by the selected CoNS species by quantifying the total number of cultivable cells (Figure 3.1) and the total biomass (Figure 3.2). Biofilms cultures were quantified after 24 h of growth.


Figure 3.1. Biofilm CFU quantification of all six CoNS. This experiment was performed *in S. haemolyticus 065A.1, S. equorum 060A, S. capitis 52A, S. warneri F16, S. hominis M11* and *S. epidermidis 20A.1*. The values represent the mean and the error bars the standard deviation of six independent experiments.

Figure 3.2. Biofilm biomass quantification of the biofilms formed by all the six CoNS. This experiment was performed *in S. haemolyticus 065A.1, S. equorum 060A, S. capitis 52A, S. warneri F16, S. hominis M11* and *S. epidermidis 20A.1*. The values represent the mean and the error bars the standard deviation of two independent experiments.

According with biofilm CFU quantification assay, all strains formed biofilms with approximately 1×10^8 CFU /mL, with exception of *S. warneri* strain F16 that showed, comparatively with the other CoNS isolates tested, lower number of cultivable cells after 24 hours of growth. As observed in Figure 3.2, the biofilms formed by this strain also showed inferior optical density, predicting a biofilm composed by fewer cells, polysaccharides, proteins and others matrix constituents (Sousa et al., 2009). Results from biofilm quantification assays allowed the preparation of planktonic cultures with the same number of cultivable cells as biofilms. This way, the results obtained in both planktonic and biofilms cultures can be compared. In order to proceed, a calibration curve was constructed to correlate the values of optical density (OD), at 640 nm, and the number of colony forming units (CFU) per mL of planktonic cells (Appendix A).

To evaluate the effect of carvacrol on biofilms, the cultivability of the bacterial cells within the biofilms as well as its tridimensional structure were assessed after different exposure times to carvacrol. Because very little is known about carvacrol effect on CoNS, many tests were performed with the intention of optimizing carvacrol antimicrobial activity.

Firstly, for comparative purposes, planktonic cultures were tested. This approach assures that if carvacrol is not efficient killing bacteria in planktonic state, on biofilms it is most likely that it will not have any significant effects either (Cargill and Upton, 2009; Ceri et al., 1999; Farber et al., 1990; Mah and O'Toole, 2001). A preliminary experiment was performed to understand how carvacrol would affect cells cultivability. Hence, it was decide to use a concentration of carvacrol of 4 × the MIC determined previously.


Figure 3.3. Planktonic cells susceptibility to carvacrol (4 × MIC). This assay was performed using both stationary and logarithmic planktonic cells of *S. equorum 060A, S. capitis 52A* and *S. warneri F16* after 3 hours of incubation with carvacrol. Error bars and *P* values were not calculated since this was a single experiment.

As can be seen in Figure 3.3, after 3 hours of incubation with carvacrol, no CFU were detected neither in stationary nor in logarithmic phases of growth. In order to better understand the results obtained, we have tested reduced exposure times (Figure 3.4). However, because this was a preliminary experiment, this was only tested on *S. epidermidis* strain *20A.1.*


Figure 3.4. *S. epidermidis 20A.1* **CFU counting after 5, 50 and 95 minutes of exposure to carvacrol (4 × MIC)**. Error bars and *P* values are not calculated since this was a single experiment.

The results obtained showed that even in lower exposure times, no CFU were observed. It was clear that at this concentration and for the tested exposure times, carvacrol was very efficient.

The following experiment was designed to determine how difference concentrations of carvacol would influence cell cultivability. On this new experiment, four different carvacrol concentrations, starting from MIC, and rising up to 2, 4 and 8 × MIC were tested, first, in *S. epidermidis*.

Figure 3.5. CFU counting after *S. epidermidis 20A.1* planktonic cells treatment with different concentrations of carvacrol. Concentrations are respectively MIC – 2 μM, 2 × MIC – 4 μM, 4 × MIC – 8 μM and 8 × MIC – 16 μM. Error bars and *P* values are not calculated since this was a single experiment.

CFU counting showed a decrease of cultivable cells with the increase of carvacrol concentration as well as exposure time. It appeared that after 50 minutes of exposure, cells lose their cultivability. In addition, it seems that for the concentration eight times higher than MIC, cells were immediately damaged, since no CFU were detected after 5 minutes of exposure.

Since this very quick effect was somewhat surprising, an extra experiment was performed. It's known that carvacrol interacts with cells' membrane by binding to the lipid bilayer (Nowotarska et al., 2014). So, it was essential to ensure that carvacrol was not carried out through the serial dilutions performed during CFU plating. To address that, before platting the cells exposed to carvacrol a washing step was performed. Figure 3.6 represents results from this experiment.

Figure 3.6. CFU counting after treatment with 2 µM of carvacrol with and without cell wash. The assay was performed once using *S. epidermidis 20A.1*. Error bars and *P* values were not calculated since this experiment was performed once.

By analyzing these results is was clear that no significant changes were observed with or without a washing step. We did not assess the short time period of exposition (5 min), since it took 10 min to centrifuge the cells and it was not possible to guarantee that during this time carvacrol was not inducing any reduction in cells cultivability. Given this outcome, it is possible to conclude that carvacrol at 2 µM, is a powerful antimicrobial agent that is capable of quickly bind to cells resulting in an absence of growth.

Since small concentrations of carvacrol had a strong effect on *S. epidermidis*, even under a short exposure time, it would be of great interest to evaluate carvacrol MIC in all the six CoNS under study. Although, this group of six species belongs to a group with similar characteristics, they can respond differently to the same stress. To pursue our objective, the susceptibility of all CoNS strains to 2 µM of carvacrol was tested.

Figure 3.7. Susceptibility of planktonic cells of all CoNS strains to carvacrol. This test was performed *in S. warneri F16, S. capitis 52A, S. equorum 060A, S. epidermidis 20A.1, S. hominis M11* and *S. haemolyticus 065A.1* in stationary phase of growth. All cells were exposed for 90 min to 2 μM of carvacrol. The values represent the mean and the error bars the standard deviation of five independent experiments. Significant differences are represented with: **a** = $P < 0.05$ and **b** = $P < 0.001$.

Although each strain responded slightly different to carvacrol MIC, all were affected by 2 μM of carvacrol. This effect can be due to the hydrophobic nature of carvacrol that favours its accumulation in the cellular membrane, possibly causing membrane disruption and resulting in the leakage of intracellular contents (Ultee et al., 1999). There was a significant decrease, in all strains, in the CFU counting after 5 min of exposure ($P < 0.05$ or $P < 0.001$). Analyzing each strain separately, *S. warneri F16, S. capitis 52A* and *S. hominis M11* had a reduction in CFU of proximally 1 Log (90% of cells), *S. haemolyticus 065A.1* 2 Log (99% of cells) and *S. equorum 060A* and *S. epidermidis 20A.1* had a reduction superior to 3 Log (> 99.9% of cells). After 50 or 95 minutes of treatment with carvacrol, an abrupt decrease in CFU was observed in all six strains, in fact, no growth was detected. In conclusion, a carvacrol concentration of 2 μM was sufficient to promote a significant reduction in planktonic cells cultivability in all six CoNS under study. Furthermore, Figure 3.5 suggested that cell damaging is directly proportional to both exposure time and carvacrol concentration.

Nevertheless, as previously shown, the decrease in cells cultivability is not always associated with cells dead but rather with the development of a dormant state (Cerca et al., 2014). Hence, in order to determine if carvacrol was inducing a viable but non-culturable state or killing bacterial cells, a LIVE/DEAD staining was performed and cells were analyzed by flow cytometry.


Figure 3.8. Percentage of dead cells after treatment with carvacrol. This assay was performed in all six CoNS under study after 95 min of incubation with 2 µM of carvacrol. Positive control (dead cells), was achieved by incubating cells with methanol for 15 min; T0 min represents cells without any treatment and T95 min represent cells after 95 min of exposure to carvacrol. Strain *S. equorum 060A* was unable to stain, even after 1 hour of incubation with a mix of SYBR and propidium iodide. This assay was performed once.

The results obtained showed that after 95 min incubation with 2 µM of carvacrol >95% of cells were dead. Since carvacrol acts on cell membrane, it is possible to conclude, that the membrane fluidity is an important factor affecting the viability of CoNS, but probably not the only factor (Ultee et al., 1998). The changes in the cellular membrane (lipid membrane composition, leakage of essential components) are definitely associated with loss of integrity and subsequent death, but more studies have to be done to obtain more insights into the mechanisms underlying carvacrol bactericidal effect (Ben Arfa et al., 2006; Cristani et al., 2007; Di Pasqua et al., 2007).

3.3| Evaluation of carvacrol activity on biofilm cultures

According to the main goal of this work, carvacrol was added to 24h biofilms of all six CoNS species under study and biofilm structure and cells cultivability was evaluated. Figure 3.9 demonstrate results from CFU counting after contact with carvacrol.


Figure 3.9. CoNS biofilms CFU reduction after exposure to carvacrol. Biofilms of *S. capitis 52A, S. equorum 060A, S. warneri F16, S. hominis M11, S. epidermidis 20A.1* and *S. haemolyticus 065A.1,* were exposed to a concentration of 2 µM of carvacrol for 95 min. The values represent the average and the error bars the standard deviation of 3 independent experiments. Significant differences are represented with: **a** = $P < 0.05$ and **b** = $P < 0.001$, when compared with the control (T0 min).

As could be expected, biofilm cells were less sensitive to carvacrol than their planktonic counterparts. It should be noted that biofilm formation depends on many intrinsic and extrinsic factors, and vary from species to species and even among strains of the same species (McLandsborough et al., 2006). Furthermore, bacteria within a biofilm is organized in aggregates, physically joined together, and protected by an extracellular matrix that contains many different types of extracellular polymeric substances (EPS) including proteins, DNA and polysaccharides that block antimicrobial treatment allowing cells to proliferate (Abdel-aziz and Aeron, 2014; Anderson and O'Toole, 2008; del Pozo and Patel, 2007). These aggregates can withstand very high

doses of antimicrobial agents inclusive antibiotics, which in planktonic cells would be lethal (Brooun et al., 2000).

Nevertheless, the observed reduction was more efficient than what has been shown in the literature, for antibiotics (Cerca et al., 2005a). In general, after 5 min of exposure to carvacrol, the strains *S. warneri F16, S. capitis 52A, S. equorum 060A, S. epidermidis 20A.1* and *S. haemolyticus 065A.1* had a significant reduction, ranging from 0.5 to 1.5 Log. After 95 min, for all CoNS isolates, the reduction was more accentuated, and in some cases (*S. equorum 060A* and *S. epidermidis 20A.1*) cell cultivability achieved reductions superior to 3 Log.

Although, biofilms infections are typically difficult to treat (Wu et al., 2014), carvacrol seems to penetrate into biofilm, and promote cell death. These results are important, since this could be a first breach in biofilm infections treatment. As far as we know, no other molecules had interacted with *S. epidermidis* biofilms and caused such a significant damage (Nostro et al., 2007). This emphasizes carvacrol antimicrobial activity and its potential to be used in biofilm infections treatment.

In order to analyze changes in biofilms structure, a confocal laser scanning microscopy analysis was performed. Pictures, of at least 3 different regions of each biofilms, were taken before and after exposure to carvacrol MIC.

◦ **Control**

◦ **Treated with carvacrol**

Figure 3.10. *S. epidermidis 20A.1* **confocal laser scanning microscopy structure images.** Effect of carvacrol on biofilm structure before (control) and 90 minutes after exposure to 2 µM of carvacrol.

◦ **Control**

◦ **Treated with carvacrol**

Figure 3.11. *S. equorum 060A 1* **confocal laser scanning microscopy structure images.** Effect of carvacrol on biofilm structure before (control) and 90 minutes after exposure to 2 µM of carvacrol.

◦ **Control**

◦ **Treated with carvacrol**

Figure 3.12. *S. haemolyticus 065A 1* **confocal laser scanning microscopy structure images.** Effect of carvacrol on biofilm structure before (control) and 90 minutes after exposure to 2 µM of carvacrol.

◦ **Control**

◦ **Treated with carvacrol**

Figure 3.13. *S. capitis 52A* **confocal laser scanning microscopy structure images.** Effect of carvacrol on biofilm structure before (control) and 90 minutes after exposure to 2 µM of carvacrol.

◦ **Control**

◦ **Treated with carvacrol**

Figure 3.14. *S. hominis M11* **confocal laser scanning microscopy structure images.** Effect of carvacrol on biofilm structure before (control) and 90 minutes after exposure to 2 µM of carvacrol.

◦ **Control**


◦ **Treated with carvacrol**

Figure 3.15. *S. warneri F16* confocal laser scanning microscopy structure images. Effect of carvacrol on biofilm structure before (control) and 90 minutes after exposure to 2 µM of carvacrol.

The obtained images confirmed that carvacrol had a great impact on biofilm thickness and density, which were strongly reduced. It seems that biofilms composed by many layers and with typical biofilm mushroom shape, like *S. epidermidis 20A.1, S. equorum 060A, S. haemolyticus 065A* and *S. hominis M11,* appeared to have relevant changes after contact with carvacrol. This could be explained due to the fact that biofilm architecture have, at their top layers, cells which are less attached to the matrix and actually in transition to phase of dispersion (Stoodley et al., 2002), making them more vulnerable to antimicrobial treatment. In addition, *S. capitis 52A* and *S. warneri F16* strains were less affected.

In addition, this data reinforces that biofilm structure density is altered when in presence of antimicrobial agents like carvacrol (Cerca et al., 2012a).

3.4| Antibiotic susceptibility assay in planktonic cultures

Being vancomycin the antibiotic of choice for the treatment of CoNS infections, it was interesting to compare the efficacy of vancomycin with the one of carvacrol. It has been previously shown that vancomycin is effective against CoNS species being therefore, one of the most frequently use antibiotics to treat nosocomial infections (Rybak, 2006). In addition, vancomycin inhibits the biosynthesis of peptidoglycan in bacterial cell wall by binding to the pentapeptide of peptidoglycan monomers and preventing the formation of peptide cross-bridges (Barna and Williams, 1984).

All strains used in this study were previously characterized in terms of antimicrobial resistance to vancomycin and were found to be susceptible to this antibiotic.

Table 3.2. Evaluation of the minimum inhibitory concentration of vancomycin on the six CoNS isolates under study. Adapted from (Oliveira, 2013).

Strain	MIC range (µg/mL)	Interpretation‡
S. equorum 060A	2	S
S. haemolyticus 065A.1	2	S
S. hominis M11	2	S
S. capitis 52A	1	S
S. warneri F16	2	S
S. epidermidis 20A.1	2 - 4	S

‡ According to EUCAST breakpoints.

The main aim of this experiment was to study the susceptibility of all CoNS planktonic cells in both stationary and exponential phases of growth towards carvacrol, and compare the results obtained with the antimicrobial effect of vancomycin, widely used in the prevention/treatment of indwelling medical device infections. Figure 3.16 shows results from this experiment.

Figure 3.16. The susceptibility of CoNS isolates to vancomycin and carvacrol. This experiment was performed in planktonic cells in both stationary and exponential phases of growth. Strains *S. warneri F16, S. capitis 52A, S. equorum 060A, S. epidermidis 20A.1, S. hominis M11* and *S. haemolyticus 065A.1* were treated, for 95 minutes, with vancomycin peak serum (PS) concentration of 40 µg/mL and with 2 µM of carvacrol. The values represent the average and the error bars the standard deviation of three independent experiments. Significant differences are represented with: **a** = $P < 0.05$; **b** = $P < 0.001$.

Surprisingly, vancomycin had almost no effect in most species tested, during the 95 minutes of exposure time tested. The response of each strain to vancomycin was very similar in both phases of growth used, with the exception of *S. warneri F16*, where the treatment of exponential planktonic cells with vancomycin significantly reduced their cultivability ($P < 0.05$), demonstrating a reduction of 1 Log (90% of cells). This direct comparison clearly demonstrated that carvacrol was more efficient in killing CoNS bacteria, than vancomycin. At 2 µM, carvacrol is able to kill bacteria from all CoNS strains tested after a short period of time.

Nevertheless, while we used the exposure time of 95 minutes, to perform the direct comparison between vancomycin and carvacrol, due to the observed low activity of vancomycin, we decided to perform an extra experiment with a longer exposure period and using strain *S. epidermidis* 9142 as an internal control, since the tolerence of this strain was previously assessed in a similar study, with vancomycin (Cerca et al., 2005a).   As shown in figure 3.17, at longer exposure periods, vancomycin caused a significant CFU reduction ($P < 0.05$) in *S. epidermidis 20A.1* strain.

These results indicate that vancomycin require more time to induce significant reduction in cells cultivability. In fact, *in vitro* studies showed that vancomycin exhibits primarily time dependent bactericidal activities and that higher drug concentrations do not correlate with more rapid killing (Estes and Derendorf, 2010; Roberts and Lipman, 2006). In addition, others studies demonstrated that vancomycin at peak serum concentration was ineffective against biofilm cells (Leite et al., 2013). Taking these results in to consideration, it was clear that vancomycin at peak serum concentration would not have any effect on CoNS biofilms. Hence, the susceptibility of biofilms to vancomycin was not assessed.

Figure 3.17. Susceptibility of *S. epidermidis 20A.1* and *S. epidermidis 9142* to vancomycin peak serum concentration. This **e**xperiment was performed in planktonic cells in exponential phase of growth. Both strains were treated, for 95 and 185 minutes, with vancomycin peak serum (VAN PS) concentration of 40 µg/mL. The values represent the average and the error bars the standard deviation of two independent experiments. Significant differences are represented with: **a** = $P < 0.05$; **b** = $P < 0.001$.

Chapter 4| Conclusions and Future work

4.1| Conclusions

Our results demonstrated that carvacrol had a significant effect in the viability of planktonic cells of the six CoNS species tested and, although less pronounced, carvacrol had also significant effect on biofilm cells. In fact, on planktonic cells, small concentrations of this antimicrobial agent were sufficient to exhibit a potent antibacterial effect. Even a 5 minutes incubation period with carvacrol at 2 µM was enough to kill 93% of planktonic and 76% of biofilm bacteria. Moreover, it was once again demonstrated that the response of planktonic cells cannot be extrapolated for biofilm cells stressing the need to have the biofilm phenotype into account in order to conceive new and effective strategies for the treatment of biofilm-related infections. Interestingly, carvacrol at 2 µM showed pronounced microbial activity when compared with the peak serum concentration of vancomycin, suggesting that carvacrol is a potential effective treatment option against *S. epidermidis* and other CoNS infections. In addition, our experiments also suggested that carvacrol action is concentration and time dependent.

4.2| Future work

In this work, a new strategy for the treatment of CoNS infections was evaluated *in vitro.* Nevertheless, to complement this work more investigations could be performed:

- Evaluation of carvacrol cytotoxicity in eukaryotic cells.

- CoNS biofilms complete eradication by exploring higher concentrations and/or longer exposure times to carvacrol.

| **Reference list**

Abdel-aziz, S.M., Aeron, A, 2014. Bacterial Biofilm: Dispersal and Inhibition Strategies. SAJ Biotechnol 1, 1–10.

Ahmad, A., Khan, A., Akhtar, F., Yousuf, S., Xess, I., Khan, L.A., Manzoor, N., 2011. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against *Candida*. Eur. J. Clin. Microbiol. Infect. Dis. 30, 41–50.

Akinkunmi, E.O., Lamikanra, A., 2010. Species distribution and antibiotic resistance in coagulase-negative staphylococci colonizing the gastrointestinal tract of children in Ile-Ife, Nigeria. Trop. J. Pharm. Res. 9, 35–43.

Alekshun, M.N., Levy, S.B., 2007. Molecular Mechanisms of Antibacterial Multidrug Resistance. Cell 128, 1037–1050.

Aligiannis, N., Kalpoutzakis, E., Mitaku, S., Chinou, I.B., 2001. Composition and Antimicrobial Activity of the Essential Oils of Two *Origanum* Species. J. Agric. Food Chem. 49, 4168–4170.

Altintas, A., Tabanca, N., Tyihák, E., Ott, P.G., Móricz, Á.M., Mincsovics, E., Wedge, D.E., 2013. Characterization of Volatile Constituents from *Origanum* onites and Their Antifungal and Antibacterial Activity. J. AOAC Int.

Anderson, G.G., O'Toole, G.A., 2008. Innate and induced resistance mechanisms of bacterial biofilms. Curr. Top. Microbiol. Immunol. 322, 85–105.

Aristatile, B., Al-Numair, K., Al-Assaf, A., Pugalendi, K., 2011. Pharmacological effect of carvacrol on d-galactosamine-induced mitochondrial enzymes and DNA damage by single-cell gel electrophoresis. J. Nat. Med. 65, 568–577.

Arunasree, K.M., 2010. Anti-proliferative effects of carvacrol on a human metastatic breast cancer cell line, MDA-MB 231. Phytomedicine 17, 581–588.

Barna, J.C., Williams, D.H., 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38, 339–357.

Başer, K.H.C., Demirci, F., 2007. 4 Chemistry of Essential Oils. Flavours Fragrances Chem. Bioprocess. Sustain. 43.

Bearden, D.T., Danziger, L.H., 2001. Mechanism of action of and resistance to quinolones. Pharmacotherapy 21, 224S–232S.

Ben Arfa, A., Combes, S., Preziosi-Belloy, L., Gontard, N., Chalier, P., 2006. Antimicrobial activity of carvacrol related to its chemical structure. Lett. Appl. Microbiol. 43, 149–154.

Bonadio, M., 2006. New strategies in the prevention of implant-associated infections. Biomed. Pharmacother. 60, 478.

Borges, A, Abreu, A C., Malheiro, J., Saavedra, M.J., Simões, M., 2013. Biofilm prevention and control by dietary phytochemicals 32–41.

Boselli, E., Breilh, D., Rimmele, T., Djabarouti, S., Toutain, J., Chassard, D., Saux, M.-C., Allaouchiche, B., 2005. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33, 1529–1533.

Boskabady, M.H., Jafari, Z., Pouraboli, I., 2011. The effect of carvacrol on muscarinic receptors of guinea-pig tracheal chains. Phyther. Res. 25, 530–535.

Brakstad, O.G., Maeland, J.A., 1997. Mechanisms of methicillin resistance in staphylococci. APMIS 105, 264–276.

Brooun, A., Liu, S., Lewis, K., 2000. A dose-response study of antibiotic resistance in *Pseudomonas aeruginosa* biofilms. Antimicrob. Agents Chemother. 44, 640–646.

Burt, S., 2004. Essential oils: Their antibacterial properties and potential applications in foods - A review. Int. J. Food Microbiol. 94, 223–253.

Butler, M.T., Wang, Q., Harshey, R.M., 2010. Cell density and mobility protect swarming bacteria against antibiotics. Proc. Natl. Acad. Sci. U. S. A. 107, 3776–3781.

Camele, I., Elshafie, H.S., Martino, L. De, Pellegrino, C., Grulova, D., Feo, V. De, Sciences, N., 2014. Chemical Composition and Biological Activity of the Essential Oil of *Origanum vulgare* ssp . hirtum from Different Areas in the Southern Apennines (Italy) 11, 639–651.

Cargill, J.S., Upton, M., 2009. Low concentrations of vancomycin stimulate biofilm formation in some clinical isolates of *Staphylococcus epidermidis*. J. Clin. Pathol. 62, 1112–1116.

Carson, C.F., Carson, C.F., Mee, B.J., Mee, B.J., Riley, T. V, Riley, T. V, 2002. Mechanism of Action of. Society 46, 1914–1920.

Cerca, F., Franca, A., Perez-Cabezas, B., Carvalhais, V., Ribeiro, A., Azeredo, J., Pier, G., Cerca, N., Vilanova, M., 2014. Dormant bacteria within *Staphylococcus epidermidis* biofilms have low inflammatory properties and maintain tolerance to vancomycin and penicillin after entering planktonic growth. J. Med. Microbiol. 63, 1274–1283.

Cerca, F., Trigo, G., Correia, A., Cerca, N., Azeredo, J., Vilanova, M., 2011. SYBR green as a fluorescent probe to evaluate the biofilm physiological state of *Staphylococcus epidermidis*, using flow cytometry. Can. J. Microbiol. 57, 850–856.

Cerca, N., Gomes, F., Pereira, S., Teixeira, P., Oliveira, R., 2012a. Confocal laser scanning microscopy analysis of *S. epidermidis* biofilms exposed to farnesol, vancomycin and rifampicin. BMC Res. Notes 5, 244.

Cerca, N., Martins, S., Cerca, F., Jefferson, K., Pier, G., Oliveira, R., Azeredo, J., 2005a. Comparative assessment of antibiotic susceptibility of Coagulase negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother 56, 331–336.

Cerca, N., Martins, S., Pier, G.B., Oliveira, R., Azeredo, J., 2005b. The relationship between inhibition of bacterial adhesion to a solid surface by sub-MICs of antibiotics and subsequent development of a biofilm. Res. Microbiol. 156, 650–655.

Cerca, N., Pier, G.B., Vilanova, M., Oliveira, R., Azaredo, J., 2012b. Influence of batch or fed-batch growth on *Staphylococcus epidermidis* biofilm formation. Changes 29, 997–1003.

Ceri, H., Olson, M.E., Stremick, C., Read, R.R., Morck, D., Buret, A, 1999. The Calgary Biofilm Device : New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms The Calgary Biofilm Device : New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. J. Clin. Microbiol. 37, 1771.

Chami, N., Bennis, S., Chami, F., Aboussekhra, A., Remmal, A., 2005. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo. Oral Microbiol. Immunol. 20, 106–111.

Cho, H., 2007. Biofilm as a protective growth mode of bacteria 9, 1–12.

Cho, S., Choi, Y., Park, S., Park, T., 2012. Carvacrol prevents diet-induced obesity by modulating gene expressions involved in adipogenesis and inflammation in mice fed with high-fat diet. J. Nutr. Biochem. 23, 192–201.

Choong, S., Whitfield, H., 2000. Biofilms and their role in infections in urology. BJU Int. 86, 935–941.

Clarke, S.R., Foster, S.J., 2006. Surface adhesins of *Staphylococcus aureus*. Adv. Microb. Physiol. 51, 187–224.

Clinical and Laboratory Standards Institute, 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard - 9th ed. CLSI document M07-A9. Wayne, PA.

Cosentino, S., Tuberoso, C.I.G., Pisano, B., Satta, M., Mascia, V., Arzedi, E., Palmas, F., 1999. In-vitro antimicrobial activity and chemical composition of Sardinian *Thymus* essential oils. Lett. Appl. Microbiol. 29, 130–135.

Costerton, J.W., Montanaro, L., Arciola, C.R., 2005. Biofilm in implant infections: its production and regulation. Int. J. Artif. Organs 28, 1062–1068.

Costerton, J.W., Stewart, P.S., Greenberg, E.P., 1999. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318–1322.

Cox, S.D., Mann, C.M., Markham, J.L., Bell, H.C., Gustafson, J.E., Warmington, J.R., Wyllie, S.G., 2000. The mode of antimicrobial action of the essential oil of *Melaleuca alternifolia* (Tea tree oil). J. Appl. Microbiol. 88, 170–175.

Cristani, M., D'Arrigo, M., Mandalari, G., Castelli, F., Sarpietro, M.G., Micieli, D., Venuti, V., Bisignano, G., Saija, A., Trombetta, D., 2007. Interaction of Four Monoterpenes Contained in Essential Oils with Model Membranes: Implications for Their Antibacterial Activity. J. Agric. Food Chem. 55, 6300–6308.

Daferera, D.J., Ziogas, B.N., Polissiou, M.G., 2000. GC-MS Analysis of Essential Oils from Some Greek Aromatic Plants and Their Fungitoxicity on Penicillium digitatum. J. Agric. Food Chem. 48, 2576–2581.

Dalleau, S., Cateau, E., Bergès, T., Berjeaud, J.M., Imbert, C., 2008. In vitro activity of terpenes against *Candida* biofilms. Int. J. Antimicrob. Agents 31, 572–576.

Darouiche, R.O., 2001. Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 33, 1567–1572.

Davies, J., Davies, D., 2010. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433.

De Beer, D., Stoodley, P., Lewandowski, Z., 1997. Measurement of local diffusion coefficients in biofilms by microinjection and confocal microscopy. Biotechnol. Bioeng. 53, 151–158.

De Sousa, J.P., Torres, R.D.A., de Azerêdo, G.A., Figueiredo, R.C.B.Q., Vasconcelos, M.A.D.S., de Souza, E.L., 2012. Carvacrol and 1,8-cineole alone or in combination at sublethal concentrations induce changes in the cell morphology and membrane permeability of *Pseudomonas fluorescens* in a vegetable-based broth. Int. J. Food Microbiol. 158, 9–13.

Del Pozo, J.L., Patel, R., 2007. The challenge of treating biofilm-associated bacterial infections. Clin. Pharmacol. Ther. 82, 204–209.

Delaquis, P.J., Stanich, K., Girard, B., Mazza, G., 2002. Antimicrobial activity of individual and mixed fractions of dill, cilantro, coriander and eucalyptus essential oils. Int. J. Food Microbiol. 74, 101–109.

Delmas, J., Chacornac, J.P., Robin, F., Giammarinaro, P., Talon, R., Bonnet, R., 2008. Evaluation of the vitek 2 system with a variety of *Staphylococcus* species. J. Clin. Microbiol. 46, 311–313.

Demetzos, C., Perdetzoglou, D.K., Tan, K., 2001. Composition and antimicrobial studies of the oils of *Origanum calcaratum Juss*. and *O. scabrum Boiss*. et Heldr. from Greece. J. Essent. Oil Res. 13, 460–462.

Di Pasqua, R., Betts, G., Hoskins, N., Edwards, M., Ercolini, D., Mauriello, G., 2007. Membrane toxicity of antimicrobial compounds from essential oils. J. Agric. Food Chem. 55, 4863–4870.

Donlan, R.M., 2001. Biofilms and device-associated infections. Emerg. Infect. Dis. 7, 277–281.

Donlan, R.M., 2002. Biofilms: Microbial life on surfaces. Emerg. Infect. Dis. 8, 881–890.

Donlan, R.M., Costerton, J.W., 2002. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167–193.

Dorman, H.J., Deans, S.G., 2000. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J. Appl. Microbiol. 88, 308–316.

Duguid, I.G., Evans, E., Brown, M.R., Gilbert, P., 1992. Effect of biofilm culture upon the susceptibility of *Staphylococcus epidermidis* to tobramycin. J. Antimicrob. Chemother. 30, 803–810.

Dunne, W.M., Mason, E.O., Kaplan, S.L., 1993. Diffusion of Rifampin and Vancomycin through a *Staphylococcus-Epidermidis* Biofilm. Antimicrob. Agents Chemother. 37, 2522–2526.

Dzidic, S., Bedeković, V., 2003. Horizontal gene transfer-emerging multidrug resistance in hospital bacteria. Acta Pharmacol. Sin. 24, 519–526.

Dzidic, S., Suskovic, J., Kos, B., 2008. Antibiotic Resistance Mechanisms in Bacteria: Biochemical and Genetic Aspects. Food Technol. Biotechnol. 46, 11–21.

Earley, S., Gonzales, A.L., Garcia, Z.I., 2010. A dietary agonist of transient receptor potential cation channel V3 elicits endothelium-dependent vasodilation. Mol. Pharmacol. 77, 612–620.

Edmond, M.B., Wallace, S.E., McClish, D.K., Pfaller, M. A, Jones, R.N., Wenzel, R.P., 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29, 239–244.

Estes, K.S., Derendorf, H., 2010. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur. J. Med. Res. 15, 533–543.

Euzéby, J.P., 1997. List of Bacterial Names with Standing in Nomenclature: a folder available on the Internet. Int. J. Syst. Bacteriol. 47, 590–592.

Faleiro, M.L., Miguel, M.G., Ladeiro, F., Venâncio, F., Tavares, R., Brito, J.C., Figueiredo, A. C., Barroso, J.G., Pedro, L.G., 2003. Antimicrobial activity of essential oils isolated from Portuguese endemic species of *Thymus*. Lett. Appl. Microbiol. 36, 35–40.

Farber, B.F., Kaplan, M.H., Clogston, A.G., 1990. *Staphylococcus epidermidis* extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J. Infect. Dis. 161, 37–40.

Fey, P.D., Olson, M.E., 2010. Current concepts in biofilm formation of *Staphylococcus epidermidis*. Futur. Microbiol 5, 917–933.

Folkesson, A., Haagensen, J. A J., Zampaloni, C., Sternberg, C., Molin, S., 2008. Biofilm induced tolerance towards antimicrobial peptides. PLoS One 3.

Freitas, R.A.J., 2003. Biocompatibility. In: Nanomedicine. Landes Bioscience, Georgetown, TX.

Frieden, T., 2013. Antibiotic resistance threats. Cdc 22–50.

Gilbert, P., Maira-Litran, T., McBain, A.J., Rickard, A.H., Whyte, F.W., 2002. The physiology and collective recalcitrance of microbial biofilm communities. Adv. Microb. Physiol. 46, 202–256.

Gill, A. O., Holley, R. A., 2006. Disruption of *Escherichia coli*, *Listeria monocytogenes* and *Lactobacillus sakei* cellular membranes by plant oil aromatics. Int. J. Food Microbiol. 108, 1–9.

Goldmann, D. A., Pier, G.B., 1993. Pathogenesis of infections related to intravascular catheterization. Clin. Microbiol. Rev. 6, 176–192+C+.

Grice, E. A, Segre, J. A, 2011. The skin microbiome. Nat. Rev. Microbiol. 9, 244–253.

Guenther, E., 1948. The essential oils, by Ernest Guenther.

Gustafson, J.E., Liew, Y.C., Chew, S., Markham, J., Bell, H.C., Wyllie, S.G., Warmington, J.R., 1998. Effects of tea tree oil on *Escherichia coli*. Lett. Appl. Microbiol. 26, 194–198.

Hajhashemi, V., Ghannadi, A., Pezeshkian, S.K., 2002. Antinociceptive and anti-inflammatory effects of *Satureja hortensis L*. extracts and essential oil. J. Ethnopharmacol. 82, 83–87.

Halebeedu, P., Kumar, G.S., Gopal, S., 2014. Revamping the role of biofilm regulating operons in device-associated Staphylococci and *Pseudomonas aeruginosa*. Indian J. Med. Microbiol. 32, 112–123.

Hall-Stoodley, L., Stoodley, P., 2009. Evolving concepts in biofilm infections. Cell. Microbiol. 11, 1034–1043.

Hausner, M., Wuertz, S., 1999. High rates of conjugation in bacterial biofilms as determined by quantitative in situ analysis. Appl. Environ. Microbiol. 65, 3710–3713.

Heilmann, C., Hussain, M., Peters, G., Götz, F., 1997. Evidence for autolysin-mediated primary attachment of *Staphylococcus epidermidis* to a polystyrene surface. Mol. Microbiol. 24, 1013–1024.

Heilmann, C., Thumm, G., Chhatwal, G.S., Hartleib, J., Uekötter, A., Peters, G., 2003. Identification and characterization of a novel autolysin (Aae) with adhesive properties from *Staphylococcus epidermidis*. Microbiology 149, 2769–2778.

Helander, I.M., Alakomi, H.L., Latva-Kala, K., Mattila-Sandholm, T., Pol, I., Smid, E.J., Gorris, L.G.M., von Wright, A., 1998. Characterization of the Action of Selected Essential Oil Components on Gram-Negative Bacteria. J. Agric. Food Chem. 46, 3590–3595.

Hogan, D., Kolter, R., 2002. Why are bacteria refractory to antimicrobials? Curr. Opin. Microbiol. 5, 472–477.

Horan, T.C., Andrus, M., Dudeck, M. A., 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36, 309–332.

Hotta, M., Nakata, R., Katsukawa, M., Hori, K., Takahashi, S., Inoue, H., 2010. Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression. J. Lipid Res. 51, 132–139.

Huebner, J., Goldmann, D. A, 1999. Coagulase-negative staphylococci: role as pathogens. Annu. Rev. Med. 50, 223–236.

Hugonnet, S., Sax, H., Eggimann, P., Chevrolet, J.C., Pittet, D., 2004. Nosocomial Bloodstream Infection and Clinical Sepsis. Emerg. Infect. Dis. 10, 76–81.

Iannitelli, A., Grande, R., di Stefano, A., di Giulio, M., Sozio, P., Bessa, L.J., Laserra, S., Paolini, C., Protasi, F., Cellini, L., 2011. Potential antibacterial activity of carvacrol-loaded poly(DL-lactide-co-glycolide) (PLGA) nanoparticles against microbial biofilm. Int. J. Mol. Sci. 12, 5039–5051.

Ilsley, B.S., Miller, H., Greathead, H., Kamel, C., 2002. Herbal sow diets boost preweaning 10, 24–25.

Jayakumar, S., Madankumar, A., Asokkumar, S., Raghunandhakumar, S., Gokula dhas, K., Kamaraj, S., Josephine Divya, M., Devaki, T., 2012. Potential preventive effect of carvacrol against diethylnitrosamine-induced hepatocellular carcinoma in rats. Mol. Cell. Biochem. 360, 51–60.

John, J.F., Harvin, A.M., 2007. History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents. Ther. Clin. Risk Manag. 3, 1143–1152.

Juliano, C., Mattana, A., Usai, M., 2000a. Composition and in vitro Antimicrobial Activity of the Essential Oil of *Thymus herba-barona* Loisel Growing Wild in Sardinia. J. Essent. Oil Res. 12, 516–522.

Juliano, C., Mattana, A., Usai, M., 2000b. Loisel Growing Wild in Sardinia. J. Essent. Oil Res. 12, 516–522.

Juven, B.J., Kanner, J., Schved, F., Weisslowicz, H., 1994. Factors that interact with the antibacterial action of thyme essential oil and its active constituents. J. Appl. Bacteriol. 76, 626–631.

Kalemba, D., Kunicka, A., 2003. Antibacterial and antifungal properties of essential oils. Curr. Med. Chem. 10, 813–829.

Karkabounas, S., Kostoula, O.K., Daskalou, T., Veltsistas, P., Karamouzis, M., Zelovitis, I., Metsios, A., Lekkas, P., Evangelou, A.M., Kotsis, N., Skoufos, I., 2006. Anticarcinogenic and antiplatelet effects of carvacrol. Exp. Oncol. 28, 121–125.

Karpouhtsis, I., Pardali, E., Feggou, E., Kokkini, S., Scouras, Z.G., Mavragani-Tsipidou, P., 1998. Insecticidal and Genotoxic Activities of Oregano Essential Oils. J. Agric. Food Chem. 46, 1111–1115.

Kirimer, N., Başer, K.H.C., Tümen, G., 1995. Carvacrol-rich plants in Turkey. Chem. Nat. Compd. 31, 37–41.

Kleeman, K.T., Bannerman, T.L., Kloos, W.E., 1993. Species distribution of coagulase-negative staphylococcal isolates at a community hospital and implications for selection of staphylococcal identification procedures. J. Clin. Microbiol. 31, 1318–1321.

Knowles, J., Roller, S., 2001. Efficacy of Chitosan, Carvacrol, and a Hydrogen Peroxide-Based Biocide against Foodborne Microorganisms in Suspension and Adhered to Stainless Steel. J. Food Prot.

Knowles, J.R., Roller, S., Murray, D.B., Naidu, A.S., 2005. Antimicrobial Action of Carvacrol at Different Stages of Dual-Species Biofilm Development by *Staphylococcus aureus* and *Salmonella enterica Serovar Typhimurium*. Appl. Environ. Microbiol. 71, 797–803.

Kohanski, M.A., Dwyer, D.J., Collins, J.J., 2010. How antibiotics kill bacteria: from targets to networks. Nat Rev Micro 8, 423–435.

Kokare, C.R., Chakraborty, S., Khopade, A. N., Mahadik, K.R., 2009. Biofilm: Importance and applications. Indian J. Biotechnol. 8, 159–168.

Kokkini, S., Karousou, R., Dardioti, A., Krigas, N., Lanaras, T., 1997. Autumn essential oils of Greek oregano. Phytochemistry 44, 883–886.

Lai, C.C., Wang, C.Y., Chu, C.C., Tan, C.K., Lu, C.L., Lee, Y.C., Huang, Y.T., Lee, P.I., Hsueh, P.R., 2011. Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. J. Antimicrob. Chemother. 66, 1374–1382.

Lambert, M.L., Suetens, C., Frank, U., Wolkewitz, M., 2011. Clinical impact of antimicrobial resistance: Design matters - Authors' reply. Lancet Infect. Dis. 11, 344–345.

Lambert, R.J.W., Skandamis, P.N., Coote, P.J., Nychas, G.J.E., 2001. A study of the minimum inhibitory concentration and mode of action of oregano essential oil, thymol and carvacrol. J. Appl. Microbiol. 91, 453–462.

Landa, P., Kokoska, L., Pribylova, M., Vanek, T., Marsik, P., 2009. In vitro anti-inflammatory activity of carvacrol: Inhibitory effect on COX-2 catalyzed prostaglandin E2 biosynthesisb. Arch. Pharm. Res. 32, 75–78.

Lawrence, B.M., 1984. The botanical and chemical aspects of Oregano. Perfum. flavorist 9, 41–51.

Leite, B., Gomes, F., Melo, P., Souza, C., Teixeira, P., Oliveira, R., Pizzolitto, E., 2013. N-acetylcysteine and vancomycin alone and in combination against staphylococci biofilm. Brazilian J. Biomed. Eng. 29, 184–192.

Lens-Lisbonne, C., Cremieaux, A., Maillard, C., 1987. Méthodes d'évaluation de l'activité antibactérienne des huiles essentielles : application aux essences de thym et de cannelle. J. Pharm. Belg. 42, 297–302.

Levy, S.B., Marshall, B., 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med.

Lewis, K.I.M., Lewis, K.I.M., Suspects, T.H.E.U., Suspects, T.H.E.U., 2001. Riddle of Biofilm Resistance. Society 45, 999–1007.

Longauerova, A., 2006. Coagulase negative staphylococci and their participation in pathogenesis of human infections. Bratisl. Lek. Listy 107, 448–452.

Lynch, A. S., Robertson, G.T., 2008. Bacterial and fungal biofilm infections. Annu. Rev. Med. 59, 415–428.

Mack, D., Fischer, W., Krokotsch, A., Leopold, K., Hartmann, R., Egge, H., Laufs, R., 1996. The intercellular adhesin involved in biofilm accumulation of *Staphylococcus epidermidis* is a linear B-1,6-linked glucosaminoglycan: Purification and structural analysis. J. Bacteriol. 178, 175–183.

Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., Ray, S.M., Thompson, D.L., Wilson, L.E., Fridkin, S.K., 2014. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N. Engl. J. Med. 370, 1198–1208.

Mah, T.F.C., O'Toole, G. A., 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9, 34–39.

Manabe, A., Nakayama, S., Sakamoto, K., 1987. Effects of essential oils on erythrocytes and hepatocytes from rats and dipalmitoyl phosphatidylcholine-liposomes. Jpn. J. Pharmacol. 44, 77–84.

Mansour, F.A., Zaky, M.M.M., El Morsy, T., 2009. Multi-drug resistance and slime production in coagulase negative staphylococci implicated in nosocomial infections in Mansoura hospitals. Egypt Jour Exp Biol 5, 207–214.

Marino, M., Bersani, C., Comi, G., 1999. Antimicrobial Activity of the Essential Oils of *Thymus vulgaris L*. Measured Using a Bioimpedometric Method. J. Food Prot.

Marino, M., Bersani, C., Comi, G., 2001. Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae. Int. J. Food Microbiol. 67, 187–195.

Marotti, M., Piccaglia, R., Giovanelli, E., Deans, S.G., Eaglesham, E., 1994. Effects of planting time and mineral fertilization on peppermint (Mentha x piperita L.) essential oil composition and its biological activity. Flavour Fragr. J. 9, 125–129.

Mastelić, J., Jerković, I., Blažević, I., Poljak-Blaži, M., Borović, S., Ivančić-Baće, I., Smrečki, V., Žarković, N., Brčić-Kostic, K., Vikić-Topić, D., Müller, N., 2008. Comparative Study on the Antioxidant and Biological Activities of Carvacrol, Thymol, and Eugenol Derivatives. J. Agric. Food Chem. 56, 3989–3996.

McCann, M.T., Gilmore, B.F., Gorman, S.P., 2008. *Staphylococcus epidermidis* device-related infections: pathogenesis and clinical management. J. Pharm. Pharmacol. 60, 1551–1571.

McCarty, S., Woods, E., Percival, S.L., 2014. Chapter Nine - Biofilms: From Concept to Reality. In: Percival, S.L., Williams, D.W., Randle, J., Cooper, T.B.T.-B. in I.P. and C. (Eds.), . Academic Press, Boston, pp. 143–163.

Mcgimpsey, J. A, Douglas, M.H., Klink, J.W. Van, Beauregard, D. A, Perry, N.B., 1994. Seasonal Variation in Essential Oil Yield and Composition from Naturalized *Thymus vulgaris L* . in New Zealand. Flavour Fragnenace J. 9, 347–352.

McLandsborough, L., Rodriguez, A., Pérez-Conesa, D., Weiss, J., 2006. Biofilms: At the interface between biophysics and microbiology. Food Biophys. 1, 94–114.

Melo, F.H.C., Venâncio, E.T., De Sousa, D.P., De França Fonteles, M.M., De Vasconcelos, S.M.M., Viana, G.S.B., De Sousa, F.C.F., 2010. Anxiolytic-like effect of Carvacrol (5-isopropyl-2-methylphenol) in mice: Involvement with GABAergic transmission. Fundam. Clin. Pharmacol. 24, 437–443.

Mulvey, M.R., Simor, A.E., 2009. Antimicrobial resistance in hospitals: How concerned should we be? Cmaj 180, 408–415.

Nemoto, K., Hirota, K., Ono, T., Murakami, K., Murakami, K., Nagao, D., Miyake, Y., 2000. Effect of Varidase (streptokinase) on biofilm formed by *Staphylococcus aureus*. Chemotherapy 46, 111–115.

Neu, H., Gootz, T., 1996. Antimicrobial Chemotherapy. In: Baron, S. (Ed.), Medical Microbiology. Galveston (TX): University of Texas Medical Branch at Galveston.

Neu, H.C., 1992. The crisis in antibiotic resistance. Science 257, 1064–1073.

Nnis, 2004. - National Nosocomial Infections Surveillance , Public Health Service, System Report data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32, 470–485.

Nostro, A., Blanco, A.R., Cannatelli, M. A., Enea, V., Flamini, G., Morelli, I., Roccaro, A.S., Alonzo, V., 2004. Susceptibility of methicillin-resistant staphylococci to oregano essential oil, carvacrol and thymol. FEMS Microbiol. Lett. 230, 191–195.

Nostro, A., Cellini, L., Zimbalatti, V., Blanco, A.R., Marino, A., Pizzimenti, F., Giulio, M. Di, Bisignano, G., 2012. Enhanced activity of carvacrol against biofilm of *Staphylococcus aureus* and *Staphylococcus epidermidis* in an acidic environment. APMIS 120, 967–973.

Nostro, A., Marino, A., Blanco, A.R., Cellini, L., Di Giulio, M., Pizzimenti, F., Roccaro, A.S., Bisignano, G., 2009. In vitro activity of carvacrol against staphylococcal preformed biofilm by liquid and vapour contact. J. Med. Microbiol. 58, 791–797.

Nostro, A., Papalia, T., 2012. Antimicrobial activity of carvacrol: current progress and future prospectives. Recent Pat. Antiinfect. Drug Discov. 7, 28–35.

Nostro, A., Roccaro, A.S., Bisignano, G., Marino, A., Cannatelli, M. A., Pizzimenti, F.C., Cioni, P.L., Procopio, F., Blanco, A.R., 2007. Effects of oregano, carvacrol and thymol on

Staphylococcus aureus and *Staphylococcus epidermidis* biofilms. J. Med. Microbiol. 56, 519–523.

Nowotarska, S.W., Nowotarski, K.J., Friedman, M., Situ, C., 2014. Effect of structure on the interactions between five natural antimicrobial compounds and phospholipids of bacterial cell membrane on model monolayers. Molecules 19, 7497–515.

Nychas, G.J.E., 1995. Natural antimicrobials from plants. In: Gould, G.W. (Ed.), New Methods of Food Preservation SE - 4. Springer US, pp. 58–89.

Odonkor, S.T., Addo, K.K., 2011. Review article Bacteria Resistance to Antibiotics : Recent Trends and Challenges 2, 1204–1210.

Oliveira, F.E.F. De, 2013. Diversity and characterisation of coagulase- negative staphylococci isolated from healthy individuals in Portugal. Instituto Politécnico do Porto.

Oliveira, F., Cerca, N., 2013. Antibiotic resistance and biofilm formation ability among coagulase-negative staphylococci in healthy individuals from Portugal. J. Antibiot. (Tokyo). 66, 739–741.

Oosterhaven, K., Poolman, B., Smid, E.J., 1995. S-carvone as a natural potato sprout inhibiting, fungistatic and bacteristatic compound. Ind. Crops Prod. 4, 23–31.

Otto, M., 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322, 207–228.

Otto, M., 2009. *Staphylococcus epidermidis*--the "accidental" pathogen. Nat. Rev. Microbiol. 7, 555–567.

Otto, M., 2011. *Staphylococus* colonization of the skin and and antimicrobial peptides. Expert Rev Dermatol. 5, 183–195.

Park, B.S., Choi, W.S., Kim, J.H., Kim, K.H., Lee, S.E., 2005. Monoterpenes from thyme (*Thymus vulgaris*) as potential mosquito repellents. J. Am. Mosq. Control Assoc. 21, 80–83.

Parsek, M.R., Greenberg, E.P., 2000. Acyl-homoserine lactone quorum sensing in gram-negative bacteria: a signaling mechanism involved in associations with higher organisms. Proc. Natl. Acad. Sci. U. S. A. 97, 8789–8793.

Paterson, D.L., 2001. Extended-spectrum beta-lactamases: the European experience. Curr. Opin. Infect. Dis. 14, 697–701.

Peixoto-Neves, D., Silva-Alves, K.S., Gomes, M.D.M., Lima, F.C., Lahlou, S., Magalhães, P.J.C., Ceccatto, V.M., Coelho-De-Souza, A. N., Leal-Cardoso, J.H., 2010. Vasorelaxant effects of the monoterpenic phenol isomers, carvacrol and thymol, on rat isolated aorta. Fundam. Clin. Pharmacol. 24, 341–350.

Percival, S., Malic, S., Cruz, H., Williams, D., 2011. Introduction to Biofilms. In: Percival, S., Knottenbelt, D., Cochrane, C. (Eds.), Biofilms and Veterinary Medicine SE - 2, Springer Series on Biofilms. Springer Berlin Heidelberg, pp. 41–68.

Percival, S.L., Bowler, P.., 2004. Biofilms and Their Potential Role in Wound Healing. Wounds 16, 234–240.

Pérez-Conesa, D., Cao, J., Chen, L., McLandsborough, L., Weiss, J., 2011. Inactivation of *Listeria monocytogenes* and *Escherichia coli O157:H7* Biofilms by Micelle-Encapsulated Eugenol and Carvacrol. J. Food Prot.

Pfaller, M., Herwaldt, L., 1988. Laboratory , Clinical , and Epidemiological Aspects of Coagulase-Negative Staphylococci. Clin. Microbiol. Rev. 1.

Pittet, D., Dharan, S., Touveneau, S., Sauvan, V., Perneger, T. V, 1999. Bacterial contamination of the hands of hospital staff during routine patient care. Arch. Intern. Med. 159, 821–826.

Prakash, B., Veeregowda, B.M., Krishnappa, G., 2003. Biofilms: A survival strategy of bacteria. Curr. Sci. 85, 1299–1307.

Prieto, J.M., Iacopini, P., Cioni, P., Chericoni, S., 2007. In vitro activity of the essential oils of *Origanum vulgare*, *Satureja montana* and their main constituents in peroxynitrite-induced oxidative processes. Food Chem. 104, 889–895.

Reichling, J., Schnitzler, P., Suschke, U., Saller, R., 2009. Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties--an overview. Forsch. Komplementmed. 16, 79–90.

Rivas, L., McDonnell, M.J., Burgess, C.M., O'Brien, M., Navarro-Villa, A., Fanning, S., Duffy, G., 2010. Inhibition of verocytotoxigenic *Escherichia coli* in model broth and rumen systems by carvacrol and thymol. Int. J. Food Microbiol. 139, 70–78.

Roberts, A.P., Pratten, J., Wilson, M., Mullany, P., 1999. Transfer of a conjugative transposon, Tn5397 in a model oral biofilm. FEMS Microbiol. Lett. 177, 63–66.

Roberts, J.A., Lipman, J., 2006. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet. 45, 755–773.

Rogers, K.L., Fey, P.D., Rupp, M.E., 2009. Coagulase-Negative Staphylococcal Infections. Infect. Dis. Clin. North Am. 23, 73–98.

Russo, M., Galletti, G.C., Bocchini, P., Carnacini, A., 1998. Essential Oil Chemical Composition of Wild Populations of Italian Oregano Spice (*Origanum vulgare* ssp. hirtum (Link) Ietswaart): A Preliminary Evaluation of Their Use in Chemotaxonomy by Cluster Analysis. 1. Inflorescences. J. Agric. Food Chem. 46, 3741–3746.

Rybak, M.J., 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42 Suppl 1, S35–9.

Sauer, K., Rickard, A.H., Davies, D.G., 2007. Biofilms and Biocomplexity. Microbe 2, 347–353.

Service, P.H., Services, H., 2003. special article National Nosocomial Infections Surveillance (NNIS) System Report , data summary from January 1992 through June 2003 , issued August 2003. Am. J. Infect. Control 481–498.

Shelef, L.A., 1984. Antimicrobial effects of spices. J. Food Saf. 6, 29–44.

Singh, T., Chittenden, C., 2010. Efficacy of essential oil extracts in inhibiting mould growth on panel products. Build. Environ. 45, 2336–2342.

Sivropoulou, A., Papanikolaou, E., Nikolaou, C., Kokkini, S., Lanaras, T., Arsenakis, M., 1996. Antimicrobial and Cytotoxic Activities of *Origanum* Essential Oils 8561, 1202–1205.

Skandamis, P., Koutsoumanis, K., Fasseas, K., Nychas, G.J.E., 2001. Inhibition of oregano essential oil and EDTA on *Escherichia coli O157:H7*. Ital. J. food Sci. 13, 65–75.

Solórzano-Santos, F., Miranda-Novales, M.G., 2012. Essential oils from aromatic herbs as antimicrobial agents. Curr. Opin. Biotechnol. 23, 136–141.

Sousa, C., Teixeira, P., Oliveira, R., 2009. The role of extracellular polymers on S*taphylococcus epidermidis* biofilm biomass and metabolic activity. J. Basic Microbiol. 49, 363–370.

Stewart, P.S., 2003. Diffusion in Biofilms. Society 185, 1485–1491.

Stewart, P.S., William Costerton, J., 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358, 135–138.

Stone, P.W., Pogorzelska, M., Kunches, L., Hirschhorn, L.R., 2008. Hospital staffing and health care-associated infections: a systematic review of the literature. Clin. Infect. Dis. 47, 937–944.

Stoodley, P., Sauer, K., Davies, D.G., Costerton, J.W., 2002. Biofilms as complex differentiated communities. Annu. Rev. Microbiol. 56, 187–209.

Svoboda, K., Hampson, J., 1999. Bioactivity of essential oils of selected temperate aromatic plants: antibacterial, antioxidant, antiinflammatory and other related pharmacological activities. Spec. Chem. 21st … 1–17.

Tenover, F.C., 2006. Mechanisms of antimicrobial resistance in bacteria. Am. J. Infect. Control 34.

Toole, G.O., Kaplan, H.B., Kolter, R., 2000. Biofilm Formation as Microbial Development. Annu. Rev. Microbiol. 54, 49–79.

Turnidge, J., Christiansen, K., 2005. Antibiotic use and resistance - Proving the obvious. Lancet 365, 548–549.

Ultee, A., Bennik, M.H.J., Moezelaar, R., 2002. The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen *Bacillus cereus*. Appl. Environ. Microbiol. 68, 1561–1568.

Ultee, A., Kets, E.P.W., Smid, E.J., 1999. Mechanisms of action of carvacrol on the food-borne pathogen. Appl. Environ. Microbiol. 65, 4606–4610.

Ultee, A., Smid, E.J., 2001. Influence of carvacrol on growth and toxin production by *Bacillus cereus*. Int. J. Food Microbiol. 64, 373–378.

Ultee, A., Gorris, L.G., Smid, E.J., 1998. Bactericidal activity of carvacrol towards the food-borne pathogen *Bacillus cereus*. J. Appl. Microbiol. 85, 211–218.

Ultee, A., Kets, E.P.W., Alberda, M., Hoekstra, F. A., Smid, E.J., 2000. Adaptation of the food-borne pathogen Bacillus cereus to carvacrol. Arch. Microbiol. 174, 233–238.

Vacheethasanee, K., Temenoff, J.S., Higashi, J.M., Gary, A., Anderson, J.M., Bayston, R., Marchant, R.E., 1998. Bacterial surface properties of clinically isolated *Staphylococcus epidermidis* strains determine adhesion on polyethylene. J. Biomed. Mater. Res. 42, 425–432.

Van de Braak, S.A.A.J., Leijten, G.C.J.J., Institute, A., 1994. Essential oils and oleoresins : a survey in the Netherlands and other major markets in the European Union. CBI, Centre for the Promotion of Imports from Developing Countries, Rotterdam.

Von Eiff, C., Jansen, B., Kohnen, W., Becker, K., 2005. Infections associated with medical devices: Pathogenesis, management and prophylaxis. Drugs 65, 179–214.

Von Eiff, C., Peters, G., Heilmann, C., 2002. Review Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect. Dis. 2, 677–685.

Vuong, C., Otto, M., 2002. *Staphylococcus epidermidis* infections. Microbes Infect. 4, 481–489.

Wenzel, R.P., 2007. Health care-associated infections: major issues in the early years of the 21st century. Clin. Infect. Dis. 45 Suppl 1, S85–S88.

Williams, R.J., Henderson, B., Sharp, L.J., Nair, S.P., 2002. Identification of a Fibronectin-Binding Protein from *Staphylococcus epidermidis* Identification of a Fibronectin-Binding Protein from *Staphylococcus epidermidis* 70, 6805–6810.

Wu, H., Moser, C., Wang, H.-Z., Høiby, N., Song, Z.J., 2014. Strategies for combating bacterial biofilm infections. Int. J. Oral Sci. 1–7.

Yasuda, H., Ajiki, Y., Koga, T., Kawada, H., Yokota, T., 1993. Interaction between biofilms formed by *Pseudomonas aeruginosa* and clarithromycin. Antimicrob. Agents Chemother. 37, 1749–1755.

| **Supplementary information**

Appendix A

Figure 1. Calibration curves OD vs CFU, for planktonic cells, for all CoNS under study. Correlation between number of cultivable cells and optical density at 640nm. This experiment was performed tree independent times.